<SEC-DOCUMENT>0001558370-25-008430.txt : 20250605
<SEC-HEADER>0001558370-25-008430.hdr.sgml : 20250605
<ACCEPTANCE-DATETIME>20250605160151
ACCESSION NUMBER:		0001558370-25-008430
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20250605
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250605
DATE AS OF CHANGE:		20250605

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aclaris Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001557746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				460571712
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37581
		FILM NUMBER:		251027019

	BUSINESS ADDRESS:	
		STREET 1:		701 LEE ROAD
		STREET 2:		SUITE 103
		CITY:			WAYNE
		STATE:			PA
		ZIP:			19087
		BUSINESS PHONE:		484-324-7933

	MAIL ADDRESS:	
		STREET 1:		701 LEE ROAD
		STREET 2:		SUITE 103
		CITY:			WAYNE
		STATE:			PA
		ZIP:			19087
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>acrs-20250605x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.10.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 6/5/2025 2:59:32 PM -->
<!-- iXBRL Library version: 1.0.9179.3415 -->
<!-- iXBRL Service Job ID: 4da35d47-9af9-4029-b730-08b8b94b39ef -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:acrs="http://www.aclaristx.com/20250605" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" name="dei:EntityCentralIndexKey" id="Tc_5Hn0IablO0y-JcPun28d9A_2_1">0001557746</ix:nonNumeric><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" name="dei:AmendmentFlag" id="Tc_2Hwg2sz7_kunFkyzC_husQ_3_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" name="dei:CurrentFiscalYearEndDate" id="Tc_1L1NCkpkJEyDxwJWa7clAA_4_1">--12-31</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="acrs-20250605.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001557746</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-05</xbrli:startDate><xbrli:endDate>2025-06-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;border-top:9pt double #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3ba49657_4710_40f0_b80e_509581180c1b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;letter-spacing:-0.1pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:0pt;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" name="dei:DocumentType" id="Narr_iNOLyBiE-0K4DoSoHM4L2Q"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section 13 or 15(d) of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="Narr_PTxkYtOmPESeXqdE8opc7A"><b style="font-size:9pt;font-weight:bold;">June 5, 2025</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" name="dei:EntityRegistrantName" id="Narr_rEAcB7O1iUOQ2shW0VUgUw"><b style="font-weight:bold;">Aclaris Therapeutics, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a83eb2cc_1bf4_4f51_b25b_284cc2f2a7e7"></a><a id="Tc_nPRrWwpmH0O9mMrrE6iHkA_2_0"></a><a id="Tc_8vbHVT-5bU2Ec4jfAS9Hiw_2_2"></a><a id="Tc_Yjzl1KWtBkOC9I8UQ0u3UA_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:31.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_coXjH-hIoU60DvoUajHCIA_1_0"><b style="font-size:9pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" name="dei:EntityFileNumber" id="Tc_HZ2KKVnAHEyJeFoSpjvnJQ_1_2"><b style="font-size:9pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">001-37581</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" name="dei:EntityTaxIdentificationNumber" id="Tc_ijhUFXKmKU65ScEj4jQzBg_1_4"><b style="font-size:9pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">46-0571712</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation)</p></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Commission File Number)</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(IRS Employer<br/>Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" name="dei:EntityAddressAddressLine1" id="Narr_CTR6cdhffkiHzNW4gvV4UA"><b style="font-size:9pt;font-weight:bold;">701 Lee Road</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" name="dei:EntityAddressAddressLine2" id="Narr_q7hShblITUO_ge1pR2L3vA"><b style="font-size:9pt;font-weight:bold;">Suite 103</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" name="dei:EntityAddressCityOrTown" id="Narr__8S70FRukEKodoT2JV0EHQ"><b style="font-size:9pt;font-weight:bold;">Wayne</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" name="dei:EntityAddressStateOrProvince" id="Narr_1cfKWHRhNUadxDFAsAwwHg"><b style="font-size:9pt;font-weight:bold;">PA</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" name="dei:EntityAddressPostalZipCode" id="Narr_jMEfqoTE4kqUCrYMn0yMEA"><b style="font-size:9pt;font-weight:bold;">19087</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of principal executive offices, including zip code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" name="dei:CityAreaCode" id="Narr_naR14vsZaU2CErYCvu_ROw"><b style="font-size:9pt;font-weight:bold;">484</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" name="dei:LocalPhoneNumber" id="Narr_7vkmsWXn60ikevZbs9bUKA"><b style="font-size:9pt;font-weight:bold;">324-7933</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former name or former address, if changed since last report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:5pt 0pt 5pt 0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_jBsHUK5W1kWxYFKn8ZKbOQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_3NSSDBZddEOUGfVvXJeeIQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;"> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_uk7Wf5eh9EOVA5TD-ftP1A"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;"> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr__X15Ps0Y7UeyorEsOfzVuQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;letter-spacing:0pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;letter-spacing:0pt;"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><span style="font-size:8pt;letter-spacing:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b) of the Act:&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_30beb46a_da73_4626_b1c2_eec2c54fea5b"></a><a id="Tc_8BCEbKKoT0Sy7OljXQAxWg_2_0"></a><a id="Tc_TZxS6-EqpE-cn5rV_wUZAg_2_2"></a><a id="Tc_VYjbgn9SfEuf3hdDSgDibA_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.0102882385%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:20.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:41.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:20.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:41.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td></tr><tr style="height:19.35pt;"><td style="vertical-align:bottom;width:34.15%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Title of Each Class:</p></td><td style="vertical-align:bottom;width:1.86%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:20.11%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:41.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;text-align:center;margin:0pt;">Name of Each Exchange on which Registered</p></td></tr><tr style="height:11.85pt;"><td style="vertical-align:bottom;width:34.15%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" name="dei:Security12bTitle" id="Tc_aDZxAWwksk2e62KiuS6o1A_3_0"><span style="font-size:9pt;">Common Stock, $0.00001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:20.11%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" name="dei:TradingSymbol" id="Tc_7EarXS1r9EWYw3TT94vKlg_3_2"><span style="font-size:9pt;">ACRS</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:41.99%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_R2bXU6Os1kGbnsYv-LvP1A_3_4"><span style="font-size:9pt;">The Nasdaq Stock Market, LLC</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_kLT3PU5s0ESJfgPFhWOtNw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;border-bottom:9pt double #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Courier New';line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_07049a9d_236e_4584_9397_bb70629cc575"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">On June 5, 2025, the stockholders of Aclaris Therapeutics, Inc. (the &#8220;<span style="font-style:italic;font-weight:bold;">Company</span>&#8221;) approved the Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan (the &#8220;<span style="font-style:italic;font-weight:bold;">2025 Plan</span>&#8221;) at the Company&#8217;s 2025 annual meeting of stockholders (the &#8220;<span style="font-style:italic;font-weight:bold;">Annual Meeting</span>&#8221;). The Company&#8217;s Board of Directors (the &#8220;<span style="font-style:italic;font-weight:bold;">Board</span>&#8221;) had previously approved the 2025 Plan, subject to stockholder approval. The 2025 Plan is the successor to the Company&#8217;s 2015 Equity Incentive Plan. <span style="font-family:'timesnewroman';">On May 13, 2025, the Board also adopted forms of stock option grant notice and agreement and restricted stock unit grant notice and agreement for use with the 2025 Plan, effective upon stockholder approval of the 2025 Plan.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">A description of the material terms and conditions of the 2025 Plan are contained in the Company&#8217;s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 24, 2025 (the &#8220;<span style="font-style:italic;font-weight:bold;">Proxy Statement</span>&#8221;), under the heading &#8220;Proposal No. 4 &#8211; Approval of the Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan&#8221; and is incorporated herein by reference. <span style="font-family:'timesnewroman';">This description is not complete and is qualified in its entirety by reference to the full text of the 2025 Plan, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The forms of award notices and agreements for use with the 2025 Plan are attached as Exhibits 10.2 and 10.3 to this Current Report on Form 8-K and are incorporated herein by reference.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Item 5.03 &#160;Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span>At the Annual Meeting, the stockholders of the Company approved an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 200,000,000 shares to 400,000,000 shares. The increase in the authorized number of shares of the Company&#8217;s common stock was effected pursuant to a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (the &#8220;<span style="font-style:italic;font-weight:bold;">Certificate of Amendment</span>&#8221;) filed with the Secretary of State of the State of Delaware on June 5, 2025 and was effective as of such date. The foregoing description of the Certificate of Amendment <span style="font-family:'timesnewroman';">is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which </span>is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated by reference herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Item 5.07 Submission of Matters to a Vote of Security Holders.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On June 5, 2025, the Company held the Annual Meeting. The stockholders considered five proposals, each of which is described in more detail in the Proxy Statement.&#160;&#160;Of the 108,281,239&#160;shares outstanding as of the record date, 82,861,511 shares, or approximately 76.5%, were present or represented by proxy at the Annual Meeting.&#160;&#160;Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Proposal No. 1</b>:&#160;&#160;The stockholders elected three nominees to serve as directors on the Board until the 2028 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160; </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:93%;background:#ffffff;"><tr style="height:1pt;"><td style="vertical-align:top;width:42.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:15.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:17.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:42.21%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:top;width:2.22%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:15.96%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Votes&#160;For</b></p></td><td style="vertical-align:top;width:2.96%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:15.84%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Votes&#160;Withheld</b></p></td><td style="vertical-align:top;width:2.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:17.82%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Broker Non-Votes</b></p></td></tr><tr><td style="vertical-align:top;width:42.21%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Neal Walker</p></td><td style="vertical-align:top;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:15.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">71,892,109</p></td><td style="vertical-align:top;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15.84%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">796,191</p></td><td style="vertical-align:top;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:17.82%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10,173,211</p></td></tr><tr><td style="vertical-align:top;width:42.21%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Andrew Schiff, M.D.</p></td><td style="vertical-align:top;width:2.22%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:15.96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">71,700,813</p></td><td style="vertical-align:top;width:2.96%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;white-space:nowrap;width:15.84%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">987,487</p></td><td style="vertical-align:top;width:2.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:17.82%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10,173,211</p></td></tr><tr><td style="vertical-align:top;width:42.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">William Humphries</p></td><td style="vertical-align:top;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:15.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">56,697,844</p></td><td style="vertical-align:top;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15,990,456</p></td><td style="vertical-align:top;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:17.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10,173,211</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Proposal No. 2</b>: &#160;The stockholders approved, on an advisory basis, the compensation of the Company&#8217;s named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:70.99%;background:#ffffff;"><tr style="height:1pt;"><td style="vertical-align:top;width:14.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:top;width:12.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:20.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:20.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:23.37%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Votes For</b></p></td><td style="vertical-align:top;width:3.73%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:20.93%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Votes Against</b></p></td><td style="vertical-align:top;width:3.88%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:20.77%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Abstained</b></p></td><td style="vertical-align:top;width:3.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.35%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Broker Non-Votes</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:23.37%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">55,498,271</p></td><td style="vertical-align:top;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;white-space:nowrap;width:20.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16,981,505</p></td><td style="vertical-align:top;width:3.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:20.77%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">208,524</p></td><td style="vertical-align:top;width:3.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.35%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10,173,211</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Proposal No. 3</b>: &#160;The stockholders approved the Certificate of Amendment. The votes were cast as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:51.62%;background:#ffffff;"><tr style="height:1pt;"><td style="vertical-align:top;width:19.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:top;width:17.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:29.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:5.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:28.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:15pt;"><td colspan="2" style="vertical-align:top;width:31.78%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Votes For</b></p></td><td style="vertical-align:top;width:5%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:29.11%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Votes Against</b></p></td><td style="vertical-align:top;width:5.2%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:28.89%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Abstained</b></p></td></tr><tr style="height:15pt;"><td colspan="2" style="vertical-align:top;width:31.78%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">79,590,285</p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;white-space:nowrap;width:29.11%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3,035,422</p></td><td style="vertical-align:top;width:5.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:28.89%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">235,804</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Proposal No. 4</b>:&#160;&#160;The stockholders approved the 2025 Plan. The votes were cast as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:70.99%;background:#ffffff;"><tr style="height:1pt;"><td style="vertical-align:top;width:14.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:top;width:12.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:20.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:20.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:23.37%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Votes For</b></p></td><td style="vertical-align:top;width:3.73%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:20.93%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Votes Against</b></p></td><td style="vertical-align:top;width:3.88%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:20.77%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Abstained</b></p></td><td style="vertical-align:top;width:3.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.35%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Broker Non-Votes</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:23.37%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">56,963,260</p></td><td style="vertical-align:top;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;white-space:nowrap;width:20.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15,536,097</p></td><td style="vertical-align:top;width:3.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:20.77%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">188,943</p></td><td style="vertical-align:top;width:3.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.35%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10,173,211</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Proposal No. 5: </b>The stockholders ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025. The votes were cast as follows: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160; </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:51.87%;background:#ffffff;"><tr style="height:1pt;"><td style="vertical-align:top;width:30.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:29.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:5.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:29.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:15pt;"><td style="vertical-align:top;width:30.9%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Votes For</b></p></td><td style="vertical-align:top;width:4.81%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:29.86%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Votes Against</b></p></td><td style="vertical-align:top;width:5.01%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:29.39%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Abstained</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:top;width:30.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">82,516,266</p></td><td style="vertical-align:top;width:4.81%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;white-space:nowrap;width:29.86%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">328,439</p></td><td style="vertical-align:top;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.39%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16,806</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 9.01 Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(d)&#160;Exhibits</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:13.29%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:13.29%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:top;width:1.38%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:top;width:1.38%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:85.31%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></td></tr><tr><td style="vertical-align:top;width:13.29%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.5pt 0pt;">3.1</p></td><td style="vertical-align:top;width:1.38%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:85.31%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.5pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="acrs-20250605xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant.</span></a> </p></td></tr><tr><td style="vertical-align:top;width:13.29%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.5pt 0pt;">10.1</p></td><td style="vertical-align:top;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.31%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.5pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="acrs-20250605xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan.</span></a></p></td></tr><tr><td style="vertical-align:top;width:13.29%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.5pt 0pt;">10.2</p></td><td style="vertical-align:top;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.31%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.5pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="acrs-20250605xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Grant Notice and Option Agreement used in connection with the Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan.</span></a></p></td></tr><tr><td style="vertical-align:top;width:13.29%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.5pt 0pt;">10.3</p></td><td style="vertical-align:top;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.31%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.5pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="acrs-20250605xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement used in connection with the Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan.</span></a></p></td></tr><tr style="height:9pt;"><td style="vertical-align:top;width:13.29%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;">104</p></td><td style="vertical-align:top;width:1.38%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:85.31%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 1pt 0pt;"><span style="color:#212529;background:#ffffff;">The cover page from Aclaris Therapeutics, Inc.&#8217;s Form 8-K filed on June 5, 2025, formatted in Inline XBRL.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:34pt;background:#ffffff;margin:0pt 0pt 0pt 2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:34pt;background:#ffffff;margin:0pt 0pt 0pt 2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_Hlk130806694"></a><a id="_abfa48e0_b152_4b22_8e68_102433caa34d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;letter-spacing:-0.1pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:0pt;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;text-align:justify;text-indent:37.05pt;margin:0pt;"><span style="letter-spacing:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.7pt;padding-right:0.7pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.29%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">ACLARIS THERAPEUTICS, INC.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.29%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Kevin Balthaser</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="white-space:pre-wrap;">Date:  June 5, 2025</span></p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.29%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Kevin Balthaser</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.29%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-top:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-top:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>acrs-20250605xex3d1.htm
<DESCRIPTION>EX-3.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 6/5/2025 02:59:29 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 3.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATE OF AMENDMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ACLARIS THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">ACLARIS THERAPEUTICS, Inc.</b>, a corporation organized and existing under the laws of the State of Delaware (the &#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221;), does hereby certify as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">FIRST:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b>The name of the Company is Aclaris Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">SECOND:</b></font>The Company&#8217;s original Certificate of Incorporation was filed on July 13, 2012 (as amended to date, the &#8220;<font style="font-style:italic;font-weight:bold;">Certificate</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">THIRD:</b></font>The Company&#8217;s Board of Directors and stockholders, acting in accordance with the provisions of Sections&#160;141 and 242 of the General Corporation Law of the State of Delaware (&#8220;<font style="font-style:italic;font-weight:bold;">DGCL</font>&#8221;), adopted resolutions approving the following amendment to the Certificate:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The second sentence of paragraph A of Article IV of the Certificate is deleted and replaced in its entirety with:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;The total number of shares of all classes of capital stock which the Company shall have authority to issue is four hundred ten million (410,000,000) shares, of which four hundred million (400,000,000) shares shall be Common Stock (the &#8220;<font style="font-style:italic;font-weight:bold;">Common Stock</font>&#8221;), each having a par value of one-thousandth of one cent ($0.00001), and ten million (10,000,000) shares shall be Preferred Stock (the &#8220;<font style="font-style:italic;font-weight:bold;">Preferred Stock</font>&#8221;), each having a par value of one-thousandth of one cent ($0.00001).&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">FOURTH</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">:</b></font>All other provisions of the Certificate will remain in full force and effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">FIFTH</b><b style="font-weight:bold;">:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b>This Certificate of Amendment has been duly adopted in accordance with the provisions of Section 242 of the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">[Signature Page Follows]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, this Certificate of Amendment to Amended and Restated Certificate of Incorporation has been executed by a duly authorized officer of the Company on June 5th, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:48.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:51.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Aclaris Therapeutics, Inc.</b></p></td></tr><tr><td style="vertical-align:top;width:48.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:51.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-variant:small-caps;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:51.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-variant:small-caps;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Neal Walker</p></td></tr><tr><td style="vertical-align:top;width:48.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Neal Walker</p></td></tr><tr><td style="vertical-align:top;width:48.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>acrs-20250605xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 6/5/2025 02:59:30 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ACLARIS THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2025 EQUITY INCENTIVE PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-weight:bold;">General</b><font style="font-variant:small-caps;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Successor to Prior Plan</b>. This Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan (as it may be amended from time to time, the &#8220;<font style="font-style:italic;font-weight:bold;">Plan</font>&#8221;) is intended as the successor to the Aclaris Therapeutics, Inc. 2015 Equity Incentive Plan, as amended from time to time (the &#8220;<font style="font-style:italic;font-weight:bold;">Prior Plan</font>&#8221;). From and after 12:01 a.m. Eastern Time on the date this Plan is first approved by the Company&#8217;s stockholders (the &#8220;<font style="font-style:italic;font-weight:bold;">Stockholder Approval Date</font>&#8221;), no additional stock awards may be granted under the Prior Plan. Any award granted on or after 12:01 a.m. Eastern Time on the Stockholder Approval Date will be granted under this Plan. All stock awards granted under the Prior Plan will remain subject to the terms of the Prior Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font>Any shares that would otherwise remain available for future grants under the Prior Plan (the &#8220;<font style="font-style:italic;font-weight:bold;">Prior Plan&#8217;s Available Reserve</font>&#8221;) will cease to be available under the Prior Plan as of 12:01 Eastern Time on the Stockholder Approval Date. Instead, that number of shares of Common Stock equal to the Prior Plan&#8217;s Available Reserve will be added to the Share Reserve (as further described in Section 3(a) below) and be then immediately available for grants and issuance pursuant to Stock Awards under the Plan, up to the maximum number set forth in Section 3(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font> In addition, from and after 12:01 a.m. Eastern Time on the Stockholder Approval Date, any shares subject to outstanding stock awards granted under the Prior Plan or the Company&#8217;s 2012 Equity Compensation Plan that would, but for the operation of this paragraph, subsequently return to the share reserve of the Prior Plan under its terms (the &#8220;<font style="font-style:italic;font-weight:bold;">Returning Shares</font>&#8221;), such shares will not return to the reserve of the Prior Plan, and instead that number of shares of Common Stock equal to the Returning Shares will immediately be added to the Share Reserve as and when the share becomes a Returning Share, up to the maximum number set forth in Section 3(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Eligible Award Recipients</b>. Employees, Directors and Consultants are eligible to receive Awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-weight:bold;">Available Awards</b>. The Plan provides for the grant of the following types of Awards: (i)&#160;Incentive Stock Options, (ii)&#160;Nonstatutory Stock Options, (iii)&#160;Stock Appreciation Rights, (iv)&#160;Restricted Stock Awards, (v)&#160;Restricted Stock Unit Awards, (vi) Performance Cash Awards and (vii)&#160;Other Stock Awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font><b style="font-weight:bold;">Purpose</b>. The Plan, through the grant of Awards, is intended to help the Company secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide a means by which the eligible recipients may benefit from increases in value of the Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-weight:bold;">Administration</b><font style="font-variant:small-caps;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Administration by the Board</b>. The Board will administer the Plan. The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section&#160;2(c).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Powers of the Board</b>. The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font>To determine (A)&#160;who will be granted Awards; (B)&#160;when and how each Award will be granted; (C)&#160;what type of Award will be granted; (D)&#160;the provisions of each Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock under the Award; (E)&#160;the number of shares of Common Stock subject to, or the cash value of, a Stock Award; and (F)&#160;the Fair Market Value applicable to a Stock Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font>To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it will deem necessary or expedient to make the Plan or Award fully effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iii)</b></font>To settle all controversies regarding the Plan and Awards granted under it.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iv)</b></font>To accelerate, in whole or in part, the time at which an Award may be exercised or vest (or the time at which cash or shares of Common Stock may be issued in settlement thereof).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(v)</b></font>To suspend or terminate the Plan at any time. Except as otherwise provided in the Plan or an Award Agreement, suspension or termination of the Plan will not impair a Participant&#8217;s rights under the Participant&#8217;s then-outstanding Award without the Participant&#8217;s written consent except as provided in subsection&#160;(viii) below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(vi)</b></font>To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section&#160;409A of the Code and/or bringing the Plan or Awards granted under the Plan into compliance with the requirements for Incentive Stock Options or ensuring that they are exempt from, or compliant with, the requirements for nonqualified deferred compensation under Section&#160;409A of the Code, subject to the limitations, if any, of applicable law. If required by applicable law or listing requirements, and except as provided in Section&#160;9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that (A)&#160;materially increases the number of shares of Common Stock available for issuance under the Plan, (B)&#160;materially expands the class of individuals eligible to receive Awards under the Plan, (C)&#160;materially increases the benefits accruing to Participants under the Plan, (D)&#160;materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, (E)&#160;materially extends the term of the Plan, or (F)&#160;materially expands the types of Awards available for issuance under the Plan. Except as otherwise provided in the Plan or an Award Agreement, no amendment of the Plan will impair a Participant&#8217;s rights under an outstanding Award without the Participant&#8217;s written consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(vii)</b></font>To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of Section&#160;422 of the Code regarding Incentive Stock Options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(viii)</b></font>To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; <i style="font-style:italic;">provided however,</i> that a Participant&#8217;s rights under any Award will not be impaired by any such amendment without the Participant&#8217;s written consent. Notwithstanding the foregoing, (1)&#160;a Participant&#8217;s rights will not be deemed to have been impaired by any such amendment if the Board, in its discretion, determines that the amendment, taken as a whole, does not</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">impair the Participant&#8217;s rights, and (2)&#160;subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected Participant&#8217;s consent (A)&#160;to maintain the qualified status of the Award as an Incentive Stock Option under Section&#160;422 of the Code; (B)&#160;to change the terms of an Incentive Stock Option, if such change results in impairment of the Award solely because it impairs the qualified status of the Award as an Incentive Stock Option under Section&#160;422 of the Code; (C)&#160;to clarify the manner of exemption from, or to bring the Award into compliance with, Section&#160;409A of the Code; or (D)&#160;to comply with other applicable laws or listing requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ix)</b></font>Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(x)</b></font>To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-weight:bold;">Delegation to Committee</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font><b style="font-weight:bold;">General</b>. The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable). Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font><b style="font-weight:bold;">Rule 16b-3 Compliance</b>. The Committee may consist solely of two or more Non-Employee Directors within the meaning of Rule 16b-3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font><b style="font-weight:bold;">Delegation to Other Person or Body</b>. The Board or any Committee may delegate to one or more persons or bodies the authority to do one or more of the following to the extent permitted by applicable law: (i) designate recipients, other than Officers, of Awards, provided that no person or body may be delegated authority to grant an Award to themselves, (ii) determine the number of shares of Common Stock subject to such Awards; and (iii) determine the terms of such Awards; provided, however, that the Board or Committee action regarding such delegation will fix the terms of such delegation in accordance with applicable law, including without limitation Sections 152 and 157 of the Delaware General Corporation Law. Unless provided otherwise in the Board or Committee action regarding such delegation, each Award granted pursuant to this section will be granted on the applicable form of Award Agreement most recently approved for use by the Board or the Committee, with any modifications necessary to incorporate or reflect the terms of such Award. Notwithstanding anything to the contrary herein, neither the Board nor any Committee may delegate authority to any person or body (who is not a Director or that is not comprised solely of Directors, respectively) the authority to determine the Fair Market Value pursuant to Section 13(v).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font><b style="font-weight:bold;">Effect of Board&#8217;s Decision</b>. All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-weight:bold;">Shares Subject to the Plan</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Share Reserve</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font>Subject to Section&#160;9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards from and after the Effective Date will not exceed 25,556,247 shares (the <font style="font-style:italic;font-weight:bold;">&#8220;Share&#160;Reserve&#8221;</font>), which number is the sum of (i) 9,000,000 new shares, <i style="font-style:italic;">plus</i> (ii) the number of shares subject to the Prior Plan&#8217;s Available Reserve in an amount not to exceed 3,962,326 shares, <i style="font-style:italic;">plus</i> (iii) the number of shares that are Returning Shares, as such shares become available from time to time, in an amount not to exceed 12,593,921 shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font>For clarity, the Share Reserve in this Section&#160;3(a) is a limitation on the number of shares of Common Stock that may be issued pursuant to the Plan. Accordingly, this Section&#160;3(a) does not limit the granting of Awards except as provided in Section&#160;7(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Reversion of Shares to the Share Reserve</b>. If a Stock Award or any portion thereof (i)&#160;expires or otherwise terminates without all of the shares covered by such Stock Award having been issued or (ii)&#160;is settled in cash (i.e., the Participant receives cash rather than stock), such expiration, termination or settlement will not reduce (or otherwise offset) the number of shares of Common Stock that may be available for issuance under the Plan. If any shares of Common Stock issued pursuant to a Stock Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required to vest such shares in the Participant, then the shares that are forfeited or repurchased will be immediately retired and resume the status of authorized and unissued shares of the capital stock of the Company, and will revert to and again become available for issuance under the Plan. Any shares withheld from delivery by the Company in satisfaction of tax withholding obligations on a Stock Award or as consideration for the exercise or purchase price of a Stock Award will again become available for issuance under the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-weight:bold;">Incentive Stock Option Limit</b>. Subject to the Share Reserve and Section&#160;9(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be a number of shares of Common Stock equal to three multiplied by the Share Reserve.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font><b style="font-weight:bold;">Limitation on Grants to Non-Employee Directors</b>. The maximum number of shares subject to Stock Awards granted under this Plan or under any other equity plan maintained by the Company during a single fiscal year to any Non-Employee Director, taken together with any cash fees paid to such Non-Employee Director during the fiscal year, will not exceed seven hundred fifty thousand dollars ($750,000) in total value (calculating the value of any such Stock Awards based on the grant date fair market value of such Stock Awards for financial reporting purposes, and excluding, for this purpose, the value of any dividend equivalent payments paid pursuant to any Award granted in a previous fiscal year).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font><b style="font-weight:bold;">Source of Shares</b>. The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-weight:bold;">Eligibility</b><font style="font-variant:small-caps;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Eligibility for Specific Awards</b>. Incentive Stock Options may be granted only to employees of the Company or a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; thereof (as such terms are defined in Sections&#160;424(e) and 424(f) of the Code). Performance Cash Awards and Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants; <i style="font-style:italic;">provided, however</i>, that Stock Awards may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &#8220;parent&#8221; of the Company, as such term is defined in Rule&#160;405, unless (i)&#160;the stock underlying such Stock Awards is treated as &#8220;service recipient stock&#8221; under Section&#160;409A of the Code (for example, because the Awards are granted pursuant to a corporate transaction such as a spin off transaction), (ii)&#160;the Company has determined that such Awards are otherwise exempt from Section&#160;409A of the Code, or (iii)&#160;the Company has determined that such Awards comply with the distribution requirements of Section&#160;409A of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Ten Percent Stockholders</b>. A Ten Percent Stockholder will not be granted an Incentive Stock Option unless the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five&#160;years from the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></font><b style="font-weight:bold;">Provisions Relating to Options and Stock Appreciation Rights</b><font style="font-variant:small-caps;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>Each Option or SAR will be in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option. Each SAR will be denominated in shares of Common Stock. The provisions of separate Options or SARs need not be identical; <i style="font-style:italic;">provided, however</i>, that each Stock Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Stock Award Agreement or otherwise) the substance of each of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Term</b>. Subject to the provisions of Section&#160;4(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of 10 years from the date of its grant or such shorter period specified in the Award Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Exercise Price</b>. Subject to the provisions of Section&#160;4(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Award is granted. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to the Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a corporate transaction and in a manner consistent with the provisions of Section&#160;409A of the Code and, if applicable, Section&#160;424(a) of the Code. The Company will not, without stockholder approval, reduce the exercise or strike price of an outstanding Option or SAR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-weight:bold;">Purchase Price for Options</b>. The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its discretion, by any combination of the methods of payment set forth below. The Board will</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">have the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment. The permitted methods of payment are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font>by cash, check, bank draft, electronic funds transfer or money order payable to the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font>pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a &#8220;broker-assisted exercise&#8221;, &#8220;same day sale&#8221;, or &#8220;sell to cover&#8221;;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iii)</b></font>by delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise. &#8220;Delivery&#8221; for these purposes, in the discretion of the Company and/or the Board, at the time a Participant exercises an Option, will include delivery to the Company of Participant&#8217;s attestation of Ownership of such shares of Common Stock in a form approved by the Company. A Participant may not exercise a Participant&#8217;s Option by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the Company&#8217;s stock;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iv)</b></font>provided that the Option is a Nonstatutory Stock Option, by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of the Option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price plus, to the extent permitted by the Company and/or Board at the time of exercise, the aggregate withholding obligations in respect of the Option exercise; provided, further that the Participant must pay any remaining balance of the aggregate exercise price not satisfied by the &#8220;net exercise&#8221; in cash or other permitted form of payment. Shares of Common Stock will no longer be subject to the Option and will not be exercisable thereafter to the extent that (A)&#160;shares issuable upon exercise are used to pay the exercise price pursuant to the &#8220;net exercise,&#8221; (B)&#160;shares are delivered to the Participant as a result of such exercise, and (C)&#160;shares are withheld to satisfy tax withholding obligations; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(v)</b></font>in any other form of legal consideration that may be acceptable to the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font><b style="font-weight:bold;">Exercise and Payment of a SAR</b>. To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such SAR. The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A)&#160;the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B)&#160;the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date. The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Stock Award Agreement evidencing such SAR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font><b style="font-weight:bold;">Transferability of Options and SARs</b>. The Board may, in its discretion, impose such limitations on the transferability of Options and SARs as the Board will determine. In the absence of such</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">a determination by the Board to the contrary, the following restrictions on the transferability of Options and SARs will apply:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font><b style="font-weight:bold;">Restrictions on Transfer</b>. An Option or SAR will not be transferable except by will or by the laws of descent and distribution (or pursuant to subsections&#160;(ii) and (iii) below), and will be exercisable during the lifetime of the Participant only by the Participant. The Board may permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities laws. Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font><b style="font-weight:bold;">Domestic Relations Orders</b>. Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation Section 1.421-1(b)(2). If an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iii)</b></font><b style="font-weight:bold;">Beneficiary Designation</b>. Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, upon the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant&#8217;s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of applicable laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(f)</b></font><b style="font-weight:bold;">Vesting Generally</b>. The total number of shares of Common Stock subject to an Option or SAR may vest and therefore become exercisable in periodic installments that may or may not be equal. The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of Performance Goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options or SARs may vary. The provisions of this Section&#160;5(f) are subject to any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(g)</b></font><b style="font-weight:bold;">Termination of Continuous Service</b>. Except as otherwise provided in the applicable Stock Award Agreement or other individual written agreement between the Company or any Affiliate and the Participant, if a Participant&#8217;s Continuous Service terminates, (i) such portion of the Option or SAR that has not vested will be forfeited upon the Participant&#8217;s termination of Continuous Service (or, if such termination is for Cause, the Option or SAR shall be forfeited in full regardless whether vested or unvested), and (ii) the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Award as of the date of termination of Continuous Service) within the period of time ending on the earlier of (i)&#160;the date three&#160;months following the termination of the Participant&#8217;s Continuous Service (or such longer or shorter period specified in the applicable Award Agreement) and (ii)&#160;the expiration of the term of the Option or SAR as set forth in the Stock Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR will terminate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(h)</b></font><b style="font-weight:bold;">Extension of Termination Date</b>. If the exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause and other than upon the Participant&#8217;s death or Disability) would be prohibited at any time solely because the issuance of shares of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i)&#160;the expiration of a total period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, and (ii)&#160;the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement. In addition, unless otherwise provided in a Participant&#8217;s Stock Award Agreement, if the sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause) would violate the Company&#8217;s insider trading policy, then the Option or SAR will terminate on the earlier of (i)&#160;the expiration of the period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company&#8217;s insider trading policy, and (ii)&#160;the expiration of the term of the Option or SAR as set forth in the applicable Stock Award Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font><b style="font-weight:bold;">Disability of Participant</b>. Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company, if a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i)&#160;the date 12&#160;months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii)&#160;the expiration of the term of the Option or SAR as set forth in the Stock Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the applicable time frame, the Option or SAR (as applicable) will terminate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(j)</b></font><b style="font-weight:bold;">Death of Participant</b>. Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company, if (i)&#160;a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s death, or (ii)&#160;the Participant dies within the period (if any) specified in the Award Agreement for exercisability after the termination of the Participant&#8217;s Continuous Service (for a reason other than death), then the Option or SAR may be exercised (to the extent the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant&#8217;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant&#8217;s death, but only within the period ending on the earlier of (i)&#160;the date 18 months following the date of death (or such longer or shorter period specified in the Stock Award Agreement), and (ii)&#160;the expiration of the term of such Option or SAR as set forth in the Stock Award Agreement. If, after the Participant&#8217;s death, the Option or SAR is not exercised within the applicable time frame, the Option or SAR (as applicable) will terminate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(k)</b></font><b style="font-weight:bold;">Termination for Cause</b>. Except as explicitly provided otherwise in a Participant&#8217;s Stock Award Agreement or other individual written agreement between the Company or any Affiliate and the Participant, if a Participant&#8217;s Continuous Service is terminated for Cause, the Option or SAR will terminate immediately upon such Participant&#8217;s termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR (whether vested or unvested) from and after the date of such termination of Continuous Service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(l)</b></font><b style="font-weight:bold;">Non-Exempt Employees</b>. If an Option or SAR is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six months following the date of grant of the Option or SAR (although the Award may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i)&#160;if such non-exempt Employee dies or suffers a Disability,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(ii)&#160;upon a Change in Control, or (iii)&#160;upon the Participant&#8217;s retirement (as such term may be defined in the Participant&#8217;s Award Agreement, in another agreement between the Participant and the Company, or, if no such definition, in accordance with the Company&#8217;s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six months following the date of grant. The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Award will be exempt from the Employee&#8217;s regular rate of pay, the provisions of this Section&#160;5(l) will apply to all Awards and are hereby incorporated by reference into such Award Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(m)</b></font><b style="font-weight:bold;">Early Exercise of Options</b>. An Option may, but need not, include a provision whereby the Optionholder may elect at any time before the Optionholder&#8217;s Continuous Service terminates to exercise the Option as to any part or all of the shares of Common Stock subject to the Option prior to the full vesting of the Option. Any unvested shares of Common Stock so purchased may be subject to a repurchase right in favor of the Company or to any other restriction the Board determines to be appropriate. The Company will not be required to exercise its repurchase right until at least six&#160;months (or such longer or shorter period of time required to avoid classification of the Option as a liability for financial accounting purposes) have elapsed following exercise of the Option unless the Board otherwise specifically provides in the Option Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.</b></font><b style="font-weight:bold;">Provisions of Awards Other than Options and SARs</b><font style="font-variant:small-caps;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Restricted Stock Awards</b>. Each Restricted Stock Award Agreement will be in such form and will contain such terms and conditions as the Board will deem appropriate. To the extent consistent with the Company&#8217;s bylaws, at the Board&#8217;s election, shares of Common Stock underlying a Restricted Stock Award may be (i)&#160;held in book entry form subject to the Company&#8217;s instructions until any restrictions relating to the Restricted Stock Award lapse; or (ii)&#160;evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board. The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical. Each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font><b style="font-weight:bold;">Consideration</b>. A Restricted Stock Award may be awarded in consideration for (A)&#160;cash, check, bank draft or money order payable to the Company, (B)&#160;past services to the Company or an Affiliate, or (C)&#160;any other form of legal consideration (including future services) that may be acceptable to the Board, in its discretion, and permissible under applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font><b style="font-weight:bold;">Vesting</b>. Shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board, including the use of Performance Goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iii)</b></font><b style="font-weight:bold;">Termination of Participant&#8217;s Continuous Service</b>. Except as otherwise provided in the applicable Restricted Stock Award Agreement or other individual written agreement between the Company or any Affiliate and the Participant, such portion of the Restricted Stock Award that has not vested will be forfeited upon the Participant&#8217;s termination of Continuous Service, and the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">held by the Participant that have not vested as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iv)</b></font><b style="font-weight:bold;">Transferability</b>. Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board determines in its discretion, so long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(v)</b></font><b style="font-weight:bold;">Dividends</b>. A Restricted Stock Award Agreement may provide that any dividends paid on the underlying Common Stock will be subject to the same vesting and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which they relate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Restricted Stock Unit Awards</b>. Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and conditions as the Board will deem appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical. Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Award Agreement or otherwise) the substance of each of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font><b style="font-weight:bold;">Consideration</b>. At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its discretion, and permissible under applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font><b style="font-weight:bold;">Vesting</b>. At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its discretion, deems appropriate, including the use of Performance Goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iii)</b></font><b style="font-weight:bold;">Payment</b>. A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iv)</b></font><b style="font-weight:bold;">Additional Restrictions</b>. At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(v)</b></font><b style="font-weight:bold;">Dividend Equivalents</b>. Dividend equivalents may be credited in respect of shares of Common Stock covered by a Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. At the discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock Unit Award in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all of the same terms and conditions of the underlying Restricted Stock Unit Award Agreement to which they relate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(vi)</b></font><b style="font-weight:bold;">Termination of Participant&#8217;s Continuous Service</b>. Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement or other individual written agreement between the Company or any Affiliate and the Participant, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#8217;s termination of Continuous Service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(vii)</b></font><b style="font-weight:bold;">Compliance with Section&#160;409A of the Code</b>. Notwithstanding anything to the contrary set forth herein, any Restricted Stock Unit Award granted under the Plan that is not exempt from the requirements of Section&#160;409A of the Code will contain such provisions so that such Restricted Stock Unit Award will comply with the requirements of Section&#160;409A of the Code. Such restrictions, if any, will be determined by the Board and contained in the Restricted Stock Unit Award Agreement evidencing such Restricted Stock Unit Award. For example, such restrictions may include, without limitation, a requirement that any Common Stock that is to be issued in a year following the year in which the Restricted Stock Unit Award vests must be issued in accordance with a fixed pre-determined schedule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-weight:bold;">Performance Cash Awards</b>. A Performance Cash Award is a cash award that is payable contingent upon the attainment during a Performance Period of certain Performance Goals. A Performance Cash Award may also require the completion of a specified period of Continuous Service. At the time of grant of a Performance Cash Award, the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be determined by the Board in its discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font><b style="font-weight:bold;">Other Stock Awards</b>. Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value of the Common Stock at the time of grant) may be granted either alone or in addition to Awards provided for under Section&#160;5 and the preceding provisions of this Section&#160;6. Subject to the provisions of the Plan, the Board will have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></font><b style="font-weight:bold;">Covenants of the Company</b><font style="font-variant:small-caps;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Availability of Shares</b>. The Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy then-outstanding Stock Awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Securities Law Compliance</b>. A Participant will not be issued any shares in respect of an Award unless either (i) the shares are registered under the Securities Act; or (ii) the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act. Each Award also must comply with other applicable law governing the Award, and a Participant will not receive such shares if the Company determines that such receipt would not be in material compliance with applicable law. The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise of the Awards; <i style="font-style:italic;">provided, however,</i> that this undertaking will not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of an Award or the subsequent issuance of cash or Common Stock pursuant to the Award if such grant or issuance would be in violation of any applicable securities law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-weight:bold;">No Obligation to Notify or Minimize Taxes</b>. The Company will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Award. Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></font><b style="font-weight:bold;">Miscellaneous</b><font style="font-variant:small-caps;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Use of Proceeds from Sales of Common Stock</b>. Proceeds from the sale of shares of Common Stock pursuant to Stock Awards will constitute general funds of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Corporate Action Constituting Grant of Awards</b>. Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action approving the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-weight:bold;">Stockholder Rights</b>. No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to a Stock Award unless and until (i)&#160;such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under the Stock Award pursuant to its terms, and (ii)&#160;the issuance of the Common Stock subject to the Stock Award has been entered into the books and records of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font><b style="font-weight:bold;">No Employment or Other Service Rights</b>. Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or will affect the right of the Company or an Affiliate to terminate (i)&#160;the employment of an Employee with or without notice and with or without cause, (ii)&#160;the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the Company or an Affiliate, or (iii)&#160;the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font><b style="font-weight:bold;">Change in Time Commitment</b>. In the event a Participant&#8217;s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board has the right in its discretion to (x)&#160;make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">that is scheduled to vest or become payable after the date of such change in time commitment, and (y)&#160;in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(f)</b></font><b style="font-weight:bold;">Incentive Stock Option Limitations</b>. To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(g)</b></font><b style="font-weight:bold;">Investment Assurances</b>. The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Stock Award, (i)&#160;to give written assurances satisfactory to the Company as to the Participant&#8217;s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that the Participant is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Stock Award; and (ii)&#160;to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award for the Participant&#8217;s own account and not with any present intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A)&#160;the issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (B)&#160;as to any particular requirement, a determination is made by the Company that such requirement need not be met in the circumstances under the then applicable securities laws. The Company may place legends on stock certificates issued under the Plan as the Company deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(h)</b></font><b style="font-weight:bold;">Withholding Obligations</b>. Unless prohibited by the terms of an Award Agreement, the Company may, in its discretion, satisfy any federal, state or local tax withholding obligation relating to an Award by any of the following means or by a combination of such means: (i)&#160;causing the Participant to tender a cash payment; (ii)&#160;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; <i style="font-style:italic;">provided, however</i>, that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax required to be withheld by law in the applicable jurisdiction (or such lesser amount as may be necessary to avoid classification of the Award as a liability for financial accounting purposes); (iii)&#160;withholding cash from an Award settled in cash; (iv)&#160;withholding payment from any amounts otherwise payable to the Participant; or (v)&#160;by such other method as may be set forth in the Award Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font><b style="font-weight:bold;">Electronic Delivery</b>. Any reference herein or in an Award Agreement to a &#8220;written&#8221; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#8217;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access). By accepting any Award the Participant consents to receive documents by electronic delivery and to participate in the Plan through any on-line electronic system established and maintained by the Company or another third party</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">selected by the Company. The form of delivery of any Common Stock (<i style="font-style:italic;">e.g.</i>, a stock certificate or electronic entry evidencing such shares) shall be determined by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(j)</b></font><b style="font-weight:bold;">Deferrals</b>. To the extent permitted by applicable law, the Board, in its discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Stock Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants. Deferrals by Participants will be made in accordance with Section&#160;409A of the Code. Consistent with Section&#160;409A of the Code, the Board may provide for distributions while a Participant is still an Employee or otherwise providing services to the Company. The Board is authorized to make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&#8217;s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(k)</b></font><b style="font-weight:bold;">Clawback/Recovery</b>. All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company has adopted, including without limitation any policy adopted pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by applicable law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a right to voluntarily terminate employment upon a &#8220;resignation for good reason,&#8221; or for a &#8220;constructive termination&#8221; or any similar term under any plan of or agreement with the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(l)</b></font><b style="font-weight:bold;">Compliance with Section&#160;409A</b>. Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A of the Code, and to the extent not so exempt, in compliance with Section 409A of the Code. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section 409A of the Code, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), (i) if the shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes &#8220;deferred compensation&#8221; under Section 409A of the Code is a &#8220;specified employee&#8221; for purposes of Section 409A of the Code, no distribution or payment of any amount that is due because of a &#8220;separation from service&#8221; (as defined in Section 409A of the Code without regard to alternative definitions thereunder) will be issued or paid before the date that is six months following the date of such Participant&#8217;s &#8220;separation from service&#8221; or, if earlier, the date of the Participant&#8217;s death, unless such distribution or payment can be made in a manner that complies with Section 409A of the Code, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule, and (ii) each payment in a series of payments under an Award will be deemed a separate payment for purposes of Section 409A of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(m)</b></font><b style="font-weight:bold;">Further Information and Action</b>. As a condition to accepting an Award, the Participant agrees to execute any additional documents or instruments necessary or desirable, as determined in the Board&#8217;s discretion, to carry out the purposes or intent of the Award, or facilitate compliance with securities and/or other regulatory requirements, in each case at the Board&#8217;s request. Without limiting the foregoing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">sentence, upon request from the Company at any time, any Participant (and any individuals affiliated with a Participant that are beneficial owners of the Company, if applicable) will promptly provide the Company with such information and take such other actions as the Company may request in connection with any obligations the Company may have under applicable law, rule, or regulation, or to comply with requests by applicable regulatory authorities. All information provided by a Participant (or an individual affiliated with a Participant) pursuant to this paragraph shall be accurate and complete. Any Participant (and any individuals affiliated with a Participant that are beneficial owners of the Company, if applicable) will submit to the Company (or other recipient as directed by the Company) any updates to such information within 15 days after any change in, or correction to, any such information. For purposes of this paragraph, the term &#8220;beneficial owner&#8221; shall have the meaning ascribed to it in the Bank Secrecy Act as amended by the Corporate Transparency Act and any regulations promulgated thereunder (as amended from time to time).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(n)</b></font><b style="font-weight:bold;">Severability</b>. If all or any part of the Plan or any Award Agreement is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of the Plan or such Award Agreement not declared to be unlawful or invalid. Any Section of the Plan or any Award Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.</b></font><b style="font-weight:bold;">Adjustments upon Changes in Common Stock; Other Corporate Events</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Capitalization Adjustments</b>. In the event of a Capitalization Adjustment, then: (i)&#160;the class(es) and maximum number of securities subject to the Plan pursuant to Section&#160;3(a), (ii)&#160;the class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section&#160;3(c), and (iii)&#160;the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards will be proportionately adjusted and such adjustment shall occur automatically. To the extent such adjustments cannot occur automatically, the Board shall have the power to make determinations as it deems necessary and its determinations and any adjustments under this section will be final, binding and conclusive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Dissolution or Liquidation</b>. Except as otherwise provided in the Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#8217;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#8217;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service, <i style="font-style:italic;">provided, however,</i> that the Board may, in its discretion, cause some or all Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-weight:bold;">Change in Control</b>. The following provisions will apply to Awards in the event of a Change in Control unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of an Award. In the event of a Change in Control, then, notwithstanding any other provision of the Plan, the Board may take one or more of the following actions with respect to Awards, contingent upon the closing or completion of the Change in Control:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font>arrange for the surviving company or acquiring company (or the surviving or acquiring company&#8217;s parent company) to assume or continue the Award or to substitute a similar award for the Award (including, but not limited to, an award to acquire the same consideration paid to the stockholders of the Company pursuant to the Change in Control);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font>arrange for the assignment of any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to the Award to the surviving company or acquiring company (or the surviving or acquiring company&#8217;s parent company);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iii)</b></font>accelerate the vesting, in whole or in part, of the Award (and, if applicable, the time at which the Award may be exercised) to a date prior to the effective time of such Change in Control as the Board determines (or, if the Board does not determine such a date, to the date that is five&#160;days prior to the effective date of the Change in Control), with such Award terminating if not exercised (if applicable) at or prior to the effective time of the Change in Control; <i style="font-style:italic;">provided, however</i>, that the Board may require Participants to complete and deliver to the Company a notice of exercise before the effective date of a Change in Control, which exercise is contingent upon the effectiveness of such Change in Control;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iv)</b></font>arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company with respect to the Award;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(v)</b></font>cancel or arrange for the cancellation of the Award, to the extent not vested or not exercised prior to the effective time of the Change in Control, in exchange for such cash consideration (including no consideration) as the Board, in its discretion, may consider appropriate; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(vi)</b></font>make a payment, in such form as may be determined by the Board equal to the excess, if any, of (A)&#160;the value of the property the Participant would have received upon the exercise of the Award immediately prior to the effective time of the Change in Control, over (B)&#160;any exercise price payable by such holder in connection with such exercise. For clarity, this payment may be zero ($0) if the value of the property is equal to or less than the exercise price. Payments under this provision may be delayed to the same extent that payment of consideration to the holders of Common Stock in connection with the Change in Control is delayed as a result of escrows, earn outs, holdbacks or any other contingencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Board need not take the same action or actions with respect to all Awards or portions thereof or with respect to all Participants. The Board may take different actions with respect to the vested and unvested portions of an Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></font><b style="font-weight:bold;">Plan Term; Earlier Termination or Suspension of the Plan</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Plan Term</b>. The Board may suspend or terminate the Plan at any time. Unless terminated sooner by the Board, the Plan will automatically terminate on the day before the 10th anniversary of the Effective Date. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">No Impairment of Rights</b>. Suspension or termination of the Plan will not impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant or as otherwise permitted in the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></font><b style="font-weight:bold;">Effective Date of Plan</b><font style="font-variant:small-caps;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Plan will become effective on the Effective Date. In addition, no Stock Award will be exercised (or, in the case of a Restricted Stock Award, Restricted Stock Unit Award or Other Stock Award, will be granted) unless and until the Plan has been approved by the stockholders of the Company, which approval will be within 12 months after the date the Plan is adopted by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.</b></font><b style="font-weight:bold;">Choice of Law</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The laws of the State of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state&#8217;s conflict of laws rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">13.</b></font><b style="font-weight:bold;">Definitions</b><font style="font-variant:small-caps;">. </font>As used in the Plan or any Award Agreement, the following definitions will apply to the capitalized terms indicated below, unless otherwise defined in the applicable Award Agreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Affiliate</font>&#8221; means, at the time of determination, any &#8220;parent&#8221; or &#8220;majority-owned subsidiary&#8221; of the Company, as such terms are defined in Rule&#160;405. The Board will have the authority to determine the time or times at which &#8220;parent&#8221; or &#8220;majority-owned subsidiary&#8221; status is determined within the foregoing definition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Award</font>&#8221; means a Stock Award or a Performance Cash Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Award Agreement</font>&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Board</font>&#8221; means the Board of Directors of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Capitalization Adjustment</font>&#8221; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(f)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Cause</font>&#8221; will have the meaning ascribed to such term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i)&#160;such Participant&#8217;s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii)&#160;such Participant&#8217;s attempted commission of, or participation in, a fraud or act of dishonesty against the Company; (iii)&#160;such Participant&#8217;s intentional, material violation of any contract or agreement between the Participant and the Company, or of any statutory duty owed to the Company; (iv)&#160;such Participant&#8217;s unauthorized use or disclosure of the Company&#8217;s confidential information or trade secrets; (v) such Participant&#8217;s violation of a Company policy; or (vi)&#160;such Participant&#8217;s gross misconduct. The determination that a termination of the Participant&#8217;s Continuous Service is either for Cause or without Cause will be made by the Company, in its discretion. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(g)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Change in Control</font>&#8221; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:31.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font> any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#8217;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control will not be deemed to occur (A) on account of the acquisition of securities of the Company directly from the Company, (B) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#8217;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, or (C) solely because the level of Ownership held by any Exchange Act Person (the &#8220;Subject Person&#8221;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control will be deemed to occur;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font>there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A) outstanding voting securities representing more than 50% of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than 50% of the combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iii)</b></font>there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iv)</b></font>individuals who, on the date the Plan is adopted by the Board, are members of the Board (the &#8220;Incumbent Board&#8221;) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member will, for purposes of this Plan, be considered as a member of the Incumbent Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Notwithstanding the foregoing or any other provision of this Plan, (A) the term Change in Control will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, and (B) the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant will supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition will apply. To the extent required for compliance with Section 409A of the Code, in no event will a Change in Control be deemed to have occurred if such transaction is not also a &#8220;change in the ownership or effective control of&#8221; the Company or &#8220;a change in the ownership of a substantial portion of the assets of&#8221; the Company as determined under Treasury Regulations Section 1.409A-3(i)(5) (without regard to any alternative definition thereunder). The Board may, in its discretion and without a Participant&#8217;s consent, amend the definition of &#8220;Change in Control&#8221; to conform to the definition of &#8220;Change in Control&#8221; under Section 409A of the Code, and the regulations thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(h)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Code</font>&#8221; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Committee</font>&#8221; means a committee of one or more Directors to whom authority has been delegated by the Board in accordance with Section&#160;2(c).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(j)</b></font> &#8220;<font style="font-style:italic;font-weight:bold;">Common Stock</font>&#8221; means the common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(k)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221; means Aclaris Therapeutics, Inc., a Delaware corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(l)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Consultant</font>&#8221; means any person, including an advisor, who is (i)&#160;engaged by the Company or an Affiliate to render consulting or advisory services (whether directly or indirectly) and is compensated for such services, or (ii)&#160;serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#8217;s securities to such person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(m)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Continuous Service</font>&#8221; means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s service with the Company or an Affiliate, will not terminate a Participant&#8217;s Continuous Service; <i style="font-style:italic;">provided, however</i>, that if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board in its discretion, such Participant&#8217;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#8217;s discretion, may determine whether Continuous Service will be considered interrupted in the case of (i)&#160;any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii)&#160;transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in the Company&#8217;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">required by law. In addition, to the extent required for exemption from or compliance with Section 409A of the Code, the determination of whether there has been a termination of Continuous Service will be made and such term will be construed in a manner that is consistent with the definition of &#8220;separation from service&#8221; as defined under Treasury Regulation Section 1.409A-1(h) (without regard to any alternative definition thereunder).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(n)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Director</font>&#8221; means a member of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(o)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Disability</font>&#8221; means, with respect to a Participant, the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than twelve&#160;(12)&#160;months as provided in Sections&#160;22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(p)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Effective Date</font>&#8221; means the effective date of this Plan, which is the earlier of (i) the Stockholder Approval Date or (ii) the date this Plan is adopted by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(q)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Employee</font>&#8221; means any person employed by the Company or an Affiliate (whether directly or indirectly, including without limitation through an engagement with a professional employer organization, employer of record or similar arrangement, and is deemed pursuant to such arrangement to be an employee of the Company or an Affiliate under applicable laws). However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(r)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Entity</font>&#8221; means a corporation, partnership, limited liability company or other entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(s)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Exchange Act</font>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(t)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Exchange Act Person</font>&#8221; means any natural person, Entity or &#8220;group&#8221; (within the meaning of Section&#160;13(d) or 14(d) of the Exchange Act), except that &#8220;Exchange&#160;Act&#160;Person&#8221; will not include (i)&#160;the Company or any Subsidiary, (ii)&#160;any employee benefit plan of the Company or any Subsidiary or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary, (iii)&#160;an underwriter temporarily holding securities pursuant to a registered public offering of such securities, (iv)&#160;an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v)&#160;any natural person, Entity or &#8220;group&#8221; (within the meaning of Section&#160;13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#8217;s then outstanding securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(u)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Fair Market Value</font>&#8221; means, as of any date, the value of the Common Stock determined as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font>If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font>Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iii)</b></font>In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(v)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Incentive Stock Option</font>&#8221; means an option granted pursuant to Section&#160;5 of the Plan that is intended to be, and that qualifies as, an &#8220;incentive stock option&#8221; within the meaning of Section&#160;422 of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(w)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Non-Employee Director</font>&#8221; means a Director who, as of the time of the determination, is not a current employee of the Company or an Affiliate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(x)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Nonstatutory Stock Option</font>&#8221; means an option granted pursuant to Section&#160;5 of the Plan that does not qualify as an Incentive Stock Option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(y)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Officer</font>&#8221; means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(z)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Option</font>&#8221; means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(aa)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Option Agreement</font>&#8221; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(bb)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Optionholder</font>&#8221; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(cc)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Other Stock Award</font>&#8221; means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section&#160;6(d).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(dd)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Own</font>,&#8221; &#8220;<font style="font-style:italic;font-weight:bold;">Owned</font>,&#8221; &#8220;<font style="font-style:italic;font-weight:bold;">Owner</font>,&#8221; &#8220;<font style="font-style:italic;font-weight:bold;">Ownership</font>&#8221; A person or Entity will be deemed to &#8220;Own,&#8221; to have &#8220;Owned,&#8221; to be the &#8220;Owner&#8221; of, or to have acquired &#8220;Ownership&#8221; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ee)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Participant</font>&#8221; means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ff)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Performance Cash Award</font>&#8221; means an Award granted under the terms and conditions of Section 6(c).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(gg)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Performance Goals</font>&#8221; means, for a Performance Period, the one or more measures of performance established by the Board, in its discretion, for the Performance Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(hh)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Performance Period</font>&#8221; means the period of time selected by the Board, in its discretion, over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#8217;s right to and the payment of an Award. Performance Periods may be of varying and overlapping duration, at the discretion of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Restricted Stock Award</font>&#8221; means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section&#160;6(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(jj)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Restricted Stock Award Agreement</font>&#8221; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(kk)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Restricted Stock Unit Award</font>&#8221; means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section&#160;6(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ll)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Restricted Stock Unit Award Agreement</font>&#8221; means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(mm)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Rule 16b-3</font>&#8221; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(nn)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Rule 405</font>&#8221; means Rule 405 promulgated under the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(oo)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Securities Act</font>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(pp)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Stock Appreciation Right</font>&#8221; or &#8220;<font style="font-style:italic;font-weight:bold;">SAR</font>&#8221; means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section&#160;5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(qq)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Stock Appreciation Right Agreement</font>&#8221; means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(rr)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Stock Award</font>&#8221; means any right to receive Common Stock granted under the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right, or any Other Stock Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ss)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Stock Award Agreement</font>&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award. Each Stock Award Agreement will be subject to the terms and conditions of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(tt)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Subsidiary</font>&#8221; means (i)&#160;any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii)&#160;any partnership, limited liability company or other entity in</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(uu)</b></font>&#8220;<font style="font-style:italic;font-weight:bold;">Ten Percent Stockholder</font>&#8221; means a person who Owns (or is deemed to Own pursuant to Section&#160;424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>acrs-20250605xex10d2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 6/5/2025 02:59:30 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Aclaris Therapeutics, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;white-space:pre-wrap;"> 2025 Equity Incentive Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Stock Option Grant Notice</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Aclaris Therapeutics, Inc. (the &#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221;), pursuant to its 2025 Equity Incentive Plan (the &#8220;<font style="font-style:italic;font-weight:bold;">Plan</font>&#8221;), hereby grants to Optionholder an option to purchase the number of shares of the Company&#8217;s Common Stock set forth below. &#160;This option is subject to all of the terms and conditions as set forth in this notice, in the Option Agreement, the Plan and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. &#160;Capitalized terms not explicitly defined herein but defined in the Plan or the Option Agreement will have the same definitions as in the Plan or the Option Agreement. If there is any conflict between the terms in this notice and the Plan, the terms of the Plan will control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="padding-left:72pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:70%;"><tr><td style="vertical-align:top;width:57.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Optionholder:</p></td><td style="vertical-align:top;width:42.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:57.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date of Grant:</p></td><td style="vertical-align:top;width:42.85%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:57.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vesting Commencement Date:</p></td><td style="vertical-align:top;width:42.85%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:57.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Number of Shares Subject to Option:</p></td><td style="vertical-align:top;width:42.85%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:57.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise Price (Per Share):</p></td><td style="vertical-align:top;width:42.85%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:57.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Exercise Price:</p></td><td style="vertical-align:top;width:42.85%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:57.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Expiration Date:</p></td><td style="vertical-align:top;width:42.85%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[&#160;&#160;&#160;&#160;&#160;]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:90pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Type of Grant:</b></font><font style="font-family:'Times New Roman';">&#9723;</font> &#160;Incentive Stock Option<sup style="font-size:7.5pt;vertical-align:top;">1</sup> &#160; <font style="font-family:'Times New Roman';">&#9723;</font> Nonstatutory Stock Option</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Exercise Schedule</b>:<font style="display:inline-block;width:10.29pt;"></font>Same as Vesting Schedule</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:90pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Vesting Schedule</b>: </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">[______________]</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:90pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Payment: </b></font>By one or a combination of the following items (described in the Option Agreement):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 90pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;">&#9723;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </font></font>By cash, check, bank draft or money order payable to the Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 90pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;">&#9723;</font></font>Pursuant to a Regulation T Program if the shares are publicly traded</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 90pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;">&#9723;</font></font>By delivery of already-owned shares if the shares are publicly traded</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 90pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;">&#9723;</font></font>If and only to the extent this option is a Nonstatutory Stock Option, and subject to the Company&#8217;s consent at the time of exercise, by a &#8220;net exercise&#8221; arrangement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 90pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Additional Terms/Acknowledgements: </b>Optionholder acknowledges receipt of, and understands and agrees to, this Stock Option Grant Notice, the Option Agreement and the Plan. &#160;Optionholder acknowledges and agrees that this Stock Option Grant Notice and the Option Agreement may not be modified, amended or revised except as provided in the Plan. &#160;Optionholder further acknowledges that as of the Date of Grant, this Stock Option Grant Notice, the Option Agreement, and the Plan set forth the entire understanding between Optionholder and the Company regarding this option award and supersede all prior oral and written agreements, promises and/or representations on that subject with the exception of (i) options previously granted and delivered to Optionholder, (ii) any compensation recovery policy</p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.5" width="25.0%" style="background-color:#000000;color:#000000;height:1.5pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">1</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">If this is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options) cannot be first <i style="font-style:italic;">exercisable</i><font style="white-space:pre-wrap;"> for more than $100,000 in value (measured by exercise price) in any calendar year.  Any excess over $100,000 is a Nonstatutory Stock Option.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">that is adopted by the Company or is otherwise required by applicable law and (iii)&#160;any written employment or severance arrangement that would provide for vesting acceleration of this option upon the terms and conditions set forth therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By accepting this option, Optionholder consents to receive such documents by electronic delivery and to participate in the Plan through an online or electronic system established and maintained by the Company or another third party designated by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:95.37%;"><tr style="height:1pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:47.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:37.96%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-variant:small-caps;font-weight:bold;">Aclaris Therapeutics, Inc.</b></p></td><td colspan="2" style="vertical-align:top;width:44.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-variant:small-caps;font-weight:bold;">Optionholder:</b></p></td></tr><tr><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:top;width:47.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:44.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.99%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Signature</font></p></td><td colspan="2" style="vertical-align:top;width:44.99%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Signature</font></p></td></tr><tr><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Title:</font></p></td><td style="vertical-align:top;width:47.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Date:</font></p></td><td style="vertical-align:top;width:37.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Date:</font></p></td><td style="vertical-align:top;width:47.99%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:37.96%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:85.5pt;text-align:justify;text-indent:-85.5pt;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Attachments</b>: &#160;Option Agreement, 2025 Equity Incentive Plan and Notice of Exercise</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:85.5pt;text-align:justify;text-indent:-85.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Attachment I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Option Agreement</b></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Aclaris Therapeutics, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;white-space:pre-wrap;"> 2025 Equity Incentive Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Option Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;white-space:pre-wrap;"> (Incentive Stock Option or Nonstatutory Stock Option)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to your Stock Option Grant Notice (&#8220;<font style="font-style:italic;font-weight:bold;">Grant Notice</font>&#8221;) and this Option Agreement, Aclaris Therapeutics, Inc. (the &#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221;) has granted you an option under its 2025 Equity Incentive Plan (the &#8220;<font style="font-style:italic;font-weight:bold;">Plan</font>&#8221;) to purchase the number of shares of the Company&#8217;s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. &#160;The option is granted to you effective as of the date of grant set forth in the Grant Notice (the &#8220;<font style="font-style:italic;font-weight:bold;">Date of Grant</font>&#8221;). &#160;If there is any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-variant:small-caps;font-weight:bold;">Vesting.</b> &#160;Subject to the provisions contained herein, your option will vest as provided in your Grant Notice. &#160;Vesting will cease upon the termination of your Continuous Service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-variant:small-caps;font-weight:bold;">Number of Shares and Exercise Price.</b> &#160;The number of shares of Common Stock subject to your option and your exercise price per share in your Grant Notice will be adjusted for Capitalization Adjustments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-variant:small-caps;font-weight:bold;">Exercise Restriction for Non-Exempt Employees.</b> &#160;If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (that is, a &#8220;<font style="font-style:italic;font-weight:bold;">Non-Exempt Employee</font>&#8221;), and except as otherwise provided in the Plan, you may not exercise your option until you have completed at least six (6) months of Continuous Service measured from the Date of Grant, even if you have already been an employee for more than six (6) months. Consistent with the provisions of the Worker Economic Opportunity Act, you may exercise your option as to any vested portion prior to such six (6) month anniversary in the case of (i) your death or disability, (ii) a Corporate Transaction in which your option is not assumed, continued or substituted, (iii) a Change in Control or (iv) your termination of Continuous Service on your &#8220;retirement&#8221; (as defined in the Company&#8217;s benefit plans).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-variant:small-caps;font-weight:bold;">Method of Payment.</b> &#160;You must pay the full amount of the exercise price for the shares you wish to exercise. &#160;You may pay the exercise price in cash or by check, bank draft or money order payable to the Company or in any other manner permitted by your Grant Notice, which may include one or more of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>Pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. &#160;This manner of payment is also known as a &#8220;broker-assisted exercise&#8221;, &#8220;same day sale&#8221;, or &#8220;sell to cover&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>By delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise. &#160;&#8220;Delivery&#8221; for these purposes, in the sole discretion of the Company at the time you exercise your option, will include delivery</p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to the Company of your attestation of ownership of such shares of Common Stock in a form approved by the Company. &#160;You may not exercise your option by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the Company&#8217;s stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>If this option is a Nonstatutory Stock Option, subject to the consent of the Company at the time of exercise, by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of your option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price. &#160;You must pay any remaining balance of the aggregate exercise price not satisfied by the &#8220;net exercise&#8221; in cash or other permitted form of payment. &#160;Shares of Common Stock will no longer be outstanding under your option and will not be exercisable thereafter if those shares (i) are used to pay the exercise price pursuant to the &#8220;net exercise,&#8221; (ii) are delivered to you as a result of such exercise, and (iii) are withheld to satisfy your tax withholding obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></font><b style="font-variant:small-caps;font-weight:bold;">Whole Shares.</b> &#160;You may exercise your option only for whole shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.</b></font><b style="font-variant:small-caps;font-weight:bold;">Securities Law Compliance.</b> &#160;In no event may you exercise your option unless the shares of Common Stock issuable upon exercise are then registered under the Securities Act or, if not registered, the Company has determined that your exercise and the issuance of the shares would be exempt from the registration requirements of the Securities Act. &#160;The exercise of your option also must comply with all other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations (including any restrictions on exercise required for compliance with Treas. Reg. 1.401(k)-1(d)(3), if applicable).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></font><b style="font-variant:small-caps;font-weight:bold;">Term.</b> &#160;You may not exercise your option before the Date of Grant or after the expiration of the option&#8217;s term. &#160;The term of your option expires, subject to the provisions of Section 5(h) of the Plan, upon the earliest of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>immediately upon the date on which the event giving rise to your termination of Continuous Service for Cause occurs (or, if required by law, the date of termination of Continuous Service for Cause);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>three (3) months after the termination of your Continuous Service for any reason other than Cause, your Disability or your death (except as otherwise provided in Section 7(d) below); <i style="font-style:italic;">provided</i>,<i style="font-style:italic;"> however</i>, that if during any part of such three (3) month period your option is not exercisable solely because of the condition set forth in the section above relating to &#8220;Securities Law Compliance,&#8221; your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service; <i style="font-style:italic;">provided further,</i> if during any part of such three (3) month period, the sale of any Common Stock received upon exercise of your option would violate the Company&#8217;s insider trading policy, then your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service during which the sale of the Common Stock received upon exercise of your option would not be in violation of the Company&#8217;s insider trading policy. &#160;Notwithstanding the foregoing, if (i) you are a Non-Exempt Employee, (ii) your Continuous Service terminates within six (6) months after the Date of Grant, and (iii) you have vested in a portion of your option at the time of your termination of Continuous Service, your option will not expire until the earlier of (x) the later of (A) the date that is seven (7) months after the Date of Grant, and (B) the date that is three (3) months after the termination of your Continuous Service, and (y) the Expiration Date;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>twelve (12) months after the termination of your Continuous Service due to your Disability (except as otherwise provided in Section 7(d)) below;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font>eighteen (18) months after your death if you die either during your Continuous Service or within three (3) months after your Continuous Service terminates for any reason other than Cause;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font>in certain circumstances upon the effective date of a Change in Control as set forth in the Plan;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(f)</b></font>the Expiration Date indicated in your Grant Notice; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(g)</b></font>the day before the tenth (10th) anniversary of the Date of Grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the Date of Grant and ending on the day three (3) months before the date of your option&#8217;s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or Disability. &#160;The Company has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will necessarily be treated as an Incentive Stock Option if you continue to provide services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three (3) months after the date your employment with the Company or an Affiliate terminates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></font><b style="font-variant:small-caps;font-weight:bold;">Exercise.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>You may exercise the vested portion of your option during its term by (i) delivering a Notice of Exercise (in a form designated by the Company) or completing such other documents and/or procedures designated by the Company for exercise and (ii) paying the exercise price and any applicable withholding taxes to the Company&#8217;s Secretary, stock plan administrator, or such other person as the Company may designate, together with such additional documents as the Company may then require.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>By exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (i) the exercise of your option, (ii) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (iii) the disposition of shares of Common Stock acquired upon such exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>By exercising your option, you agree that, in the event the Company proposes to offer for sale to the public any of its equity securities and you are so requested by the Company or any underwriter engaged by the Company in connection with such offering, you will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company held by you, for the period specified by the Company and the underwriters following the effective date of the registration statement of the Company filed under the Securities Act for such offering, such period not to exceed 180 days or such longer period as the underwriters or the Company will request to facilitate compliance with regulatory restrictions on (1) the publication or other distribution of research reports and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in applicable FINRA rules, or any successor or similar rule or regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">You further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto.&#160;In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock until the end of such period.&#160;You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this Section 8(c). The underwriters of the Company&#8217;s stock are intended third party beneficiaries of this Section 8(c) and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font>If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the Company in writing within fifteen (15) days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two (2) years after the Date of Grant or within one (1) year after such shares of Common Stock are transferred upon exercise of your option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.</b></font><b style="font-variant:small-caps;font-weight:bold;">Transferability.</b> &#160;Except as otherwise provided in this Section 9, your option is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Certain Trusts.</b> &#160;Upon receiving written permission from the Board or its duly authorized designee, you may transfer your option to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the option is held in the trust. &#160;You and the trustee must enter into transfer and other agreements required by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Domestic Relations Orders.</b> &#160;Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer. &#160;You are encouraged to discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is contained within the domestic relations order or marital settlement agreement. &#160;If this option is an Incentive Stock Option, this option may be deemed to be a Nonstatutory Stock Option as a result of such transfer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-weight:bold;">Beneficiary Designation.</b> &#160;Upon receiving written permission from the Board or its duly authorized designee, you may, by delivering written notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your death, will thereafter be entitled to exercise this option and receive the Common Stock or other consideration resulting from such exercise. &#160;In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise this option and receive, on behalf of your estate, the Common Stock or other consideration resulting from such exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></font><b style="font-variant:small-caps;font-weight:bold;">Option not a Service Contract.</b> &#160;Your option is not an employment or service contract, and nothing in your option will be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment. &#160;In addition, nothing in your option will obligate the Company or an Affiliate, their respective stockholders, boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></font><b style="font-variant:small-caps;font-weight:bold;">Withholding Obligations.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>At the time you exercise your option, in whole or in part, and at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a &#8220;same day sale&#8221; pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of your option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>If this option is a Nonstatutory Stock Option, then upon your request and subject to approval by the Company, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the maximum amount of tax required to be withheld by law in the applicable jurisdiction (or such lower amount as may be necessary to avoid classification of your option as a liability for financial accounting purposes). &#160;If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your option, share withholding pursuant to the preceding sentence shall not be permitted unless you make a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of your option. &#160;Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares of Common Stock determined as of the date of exercise of your option that are otherwise issuable to you upon such exercise. &#160;Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>You may not exercise your option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied. &#160;Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein, if applicable, unless such obligations are satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.</b></font><b style="font-variant:small-caps;font-weight:bold;">Tax Consequences</b>. You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from Section 409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal to the &#8220;fair market value&#8221; per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">13.</b></font><b style="font-variant:small-caps;font-weight:bold;">Notices.</b> &#160;Any notices provided for in your option or the Plan will be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company. &#160;The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to participate in the Plan by electronic means. &#160;By accepting this option, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">14.</b></font><b style="font-variant:small-caps;font-weight:bold;">Governing Plan Document.</b> &#160;Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. &#160;If there is any conflict between the provisions of your option and those of the Plan, the provisions of the Plan will control. &#160;In addition, your option (and any compensation paid or shares issued under your option) is subject to recoupment in accordance with The Dodd&#8211;Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">15.</b></font><b style="font-variant:small-caps;font-weight:bold;">Other Documents</b>. &#160;You hereby acknowledge receipt of and the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus. &#160;In addition, you acknowledge receipt of the Company&#8217;s policy permitting certain individuals to sell shares only during certain &#8220;window&#8221; periods and the Company&#8217;s insider trading policy, in effect from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">16.</b></font><b style="font-variant:small-caps;font-weight:bold;">Effect on Other Employee Benefit Plans</b>. &#160;The value of this option will not be included as compensation, earnings, salaries, or other similar terms used when calculating your benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#8217;s or any Affiliate&#8217;s employee benefit plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">17.</b></font><b style="font-variant:small-caps;font-weight:bold;">Voting Rights</b>. &#160;You will not have voting or any other rights as a stockholder of the Company with respect to the shares to be issued pursuant to this option until such shares are issued to you. &#160;Upon such issuance, you will obtain full voting and other rights as a stockholder of the Company. &#160;Nothing contained in this option, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">18.</b></font><b style="font-variant:small-caps;font-weight:bold;">Severability</b>. &#160;If all or any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid. &#160;Any Section of this Option Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">19.</b></font><b style="font-variant:small-caps;font-weight:bold;">Miscellaneous</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>The rights and obligations of the Company under your option will be transferable to any one or more persons or entities, and all covenants and agreements hereunder will inure to the benefit of, and be enforceable by the Company&#8217;s successors and assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>You acknowledge and agree that you have reviewed your option in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option, and fully understand all provisions of your option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font>This Option Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font>All obligations of the Company under the Plan and this Option Agreement will be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">*</font></font>*<font style="display:inline-block;width:31pt;"></font>*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">This Option Agreement will be deemed to be signed by you upon the signing by you of the Grant Notice to which it is attached.</p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Attachment II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">2025 Equity Incentive Plan</b></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Attachment III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Notice of Exercise</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Notice Of Exercise</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Aclaris Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Attention: Stock Plan Administrator</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">703 Lee Road &#8211; Suite 103</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Wayne, PA 19087</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;">Date of Exercise: _______________</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">This constitutes notice to Aclaris Therapeutics, Inc. (the &#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221;) under my stock option that I elect to purchase the below number of shares of Common Stock of the Company (the&#160;&#8220;<font style="font-style:italic;font-weight:bold;">Shares</font>&#8221;) for the price set forth below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:73.33%;"><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Type of option (check one):</p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Incentive &#160;<font style="font-family:'Times New Roman';font-size:11pt;">&#9723;</font></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Nonstatutory &#160;<font style="font-family:'Times New Roman';font-size:11pt;">&#9723;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Stock option dated:</p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">_______________</p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">_______________</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Number of Shares as<br>to which option is<br>exercised:</p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">_______________</p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">_______________</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Certificates to be<br>issued in name of:</p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">_______________</p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">_______________</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Total exercise price:</p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$______________</p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$______________</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Cash payment delivered<br>herewith:</p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$______________</p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$______________</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Value of ________ Shares delivered herewith:</p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$______________</p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$______________</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Regulation T Program (cashless exercise):</p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$______________</p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$______________</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">By this exercise, I agree (i)&#160;to provide such additional documents as you may require pursuant to the terms of the Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan, (ii)&#160;to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this option, and (iii)&#160;if this exercise relates to an Incentive Stock Option, to notify you in writing within fifteen (15) days after the date of any disposition of any of the Shares issued upon exercise of this option that occurs within two (2) years after the date of grant of this option or within one (1) year after such Shares are issued upon exercise of this option.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Very truly yours,</p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signature</p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print Name</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>5
<FILENAME>acrs-20250605xex10d3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 6/5/2025 02:59:30 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ACLARIS THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RESTRICTED STOCK UNIT GRANT NOTICE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;">(2025 EQUITY INCENTIVE PLAN)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Aclaris Therapeutics, Inc. (the &#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221;), pursuant to Section 6(b) of the Company&#8217;s 2025 Equity Incentive Plan (the &#8220;<font style="font-style:italic;font-weight:bold;">Plan</font>&#8221;), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company&#8217;s Common Stock (&#8220;<font style="font-style:italic;font-weight:bold;">Restricted Stock Units</font>&#8221;) set forth below (the &#8220;<font style="font-style:italic;font-weight:bold;">Award</font>&#8221;). The Award is subject to all of the terms and conditions as set forth in this notice of grant (this &#8220;<font style="font-style:italic;font-weight:bold;">Restricted Stock Unit Grant Notice</font>&#8221;) and in the Plan and the Restricted Stock Unit Award Agreement (the &#8220;<font style="font-style:italic;font-weight:bold;">Award Agreement</font>&#8221;), both of which are attached hereto and incorporated herein in their entirety. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan or the Award Agreement. In the event of any conflict between the terms in the Award and the Plan, the terms of the Plan shall control.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:91.72%;" align="center"><tr><td style="vertical-align:bottom;width:45.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Participant:</p></td><td style="vertical-align:bottom;width:40.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Date of Grant:</p></td><td style="vertical-align:bottom;width:40.82%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Vesting Commencement Date:</p></td><td style="vertical-align:bottom;width:40.82%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Number of Restricted Stock Units/Shares:</p></td><td style="vertical-align:bottom;width:40.82%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:108pt;text-align:justify;text-indent:-108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Vesting Schedule: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b>[&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:100.8pt;text-align:justify;text-indent:-100.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Issuance Schedule:&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b>Subject to any change on a Capitalization Adjustment, one share of Common Stock will be issued for each Restricted Stock Unit that vests at the time set forth in Section 6 of the Award Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Additional Terms/Acknowledgements:</b> &#160;Participant acknowledges receipt of, and understands and agrees to, this Restricted Stock Unit Grant Notice, the Award Agreement and the Plan. Participant further acknowledges that as of the Date of Grant, this Restricted Stock Unit Grant Notice, the Award Agreement and the Plan set forth the entire understanding between Participant and the Company regarding the acquisition of the Common Stock pursuant to the Award specified above and supersede all prior oral and written agreements on the terms of this Award with the exception, if applicable, of (i) any compensation recovery policy that is adopted by the Company or is otherwise required by applicable law, and (ii) any written employment or severance arrangement that would provide for vesting acceleration of this Award upon the terms and conditions set forth therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">By accepting this Award, Participant acknowledges having received and read this Restricted Stock Unit Grant Notice, the Award Agreement and the Plan and agrees to all of the terms and conditions set forth in these documents. &#160;Participant consents to receive Plan documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:bottom;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ACLARIS THERAPEUTICS, INC.</b></p></td><td style="vertical-align:top;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:12.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PARTICIPANT</b></p></td><td style="vertical-align:bottom;width:35.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:12.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:35.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Signature</p></td><td style="vertical-align:top;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Signature</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:12.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:35.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td colspan="2" style="vertical-align:bottom;width:44.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:44.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:12.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:35.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:85.5pt;text-align:justify;text-indent:-85.5pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:85.5pt;text-align:justify;text-indent:-85.5pt;margin:0pt;"><b style="font-weight:bold;">ATTACHMENTS</b>: &#160;&#160;&#160;&#160;&#160;Restricted Stock Unit Award Agreement and 2025 Equity Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:85.5pt;text-align:justify;text-indent:-85.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ATTACHMENT I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;">RESTRICTED STOCK UNIT AWARD AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ACLARIS THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RESTRICTED STOCK UNIT AWARD AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(2025 EQUITY INCENTIVE PLAN)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Restricted Stock Unit Grant Notice (the &#8220;<font style="font-style:italic;font-weight:bold;">Grant Notice</font>&#8221;) and this Restricted Stock Unit Award Agreement (the &#8220;<font style="font-style:italic;font-weight:bold;">Agreement</font>&#8221;), Aclaris Therapeutics, Inc. (the &#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221;) has awarded you (&#8220;<font style="font-style:italic;font-weight:bold;">Participant</font>&#8221;) a Restricted Stock Unit Award (the &#8220;<font style="font-style:italic;font-weight:bold;">Award</font>&#8221;) pursuant to Section 6(b) of the Company&#8217;s 2025 Equity Incentive Plan (the &#8220;<font style="font-style:italic;font-weight:bold;">Plan</font>&#8221;) for the number of Restricted Stock Units/shares indicated in the Grant Notice. Capitalized terms not explicitly defined in this Agreement or the Grant Notice shall have the same meanings given to them in the Plan. The terms of your Award, in addition to those set forth in the Grant Notice, are as follows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-weight:bold;">GRANT OF THE AWARD. </b>This Award represents the right to be issued on a future date one (1) share of Common Stock for each Restricted Stock Unit that vests on the applicable vesting date(s) (subject to any adjustment under Section 3 below) as indicated in the Grant Notice. As of the Date of Grant, the Company will credit to a bookkeeping account maintained by the Company for your benefit (the &#8220;<font style="font-style:italic;font-weight:bold;">Account</font>&#8221;) the number of Restricted Stock Units/shares of Common Stock subject to the Award. This Award was granted in consideration of your services to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-weight:bold;">VESTING. </b>Subject to the limitations contained herein, your Award will vest, if at all, in accordance with the vesting schedule provided in the Grant Notice, provided that vesting will cease upon the termination of your Continuous Service. Upon such termination of your Continuous Service, the Restricted Stock Units/shares of Common Stock credited to the Account that were not vested on the date of such termination will be forfeited at no cost to the Company and you will have no further right, title or interest in or to such underlying shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-weight:bold;">NUMBER OF SHARES. </b>The number of Restricted Stock Units/shares subject to your Award may be adjusted from time to time for Capitalization Adjustments, as provided in the Plan. Any additional Restricted Stock Units, shares, cash or other property that becomes subject to the Award pursuant to this Section 3, if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other Restricted Stock Units and shares covered by your Award. Notwithstanding the provisions of this Section 3, no fractional shares or rights for fractional shares of Common Stock shall be created pursuant to this Section 3. Any fraction of a share will be rounded down to the nearest whole share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-weight:bold;">SECURITIES LAW COMPLIANCE</b>. You may not be issued any Common Stock under your Award unless the shares of Common Stock underlying the Restricted Stock Units are either (i) then registered under the Securities Act, or (ii) the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act. Your Award must also comply with other applicable laws and regulations governing the Award, and you shall not receive such Common Stock if the Company determines that such receipt would not be in material compliance with such laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></font><b style="font-weight:bold;">TRANSFER RESTRICTIONS</b>. Prior to the time that shares of Common Stock have been delivered to you, you may not transfer, pledge, sell or otherwise dispose of this Award or the shares issuable in respect of your Award, except as expressly provided in this Section 5. For example, you may not use shares that may be issued in respect of your Restricted Stock Units as security for a loan. The restrictions on transfer set forth herein will lapse upon delivery to you of shares in respect of your vested Restricted Stock Units.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 4.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Death</b>. Your Award is transferable by will and by the laws of descent and distribution. At your death, vesting of your Award will cease and your executor or administrator of your</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 4.5pt;">estate shall be entitled to receive, on behalf of your estate, any Common Stock or other consideration that vested but was not issued before your death.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 4.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Domestic Relations Orders.</b> Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your right to receive the distribution of Common Stock or other consideration hereunder, pursuant to a domestic relations order or marital settlement agreement that contains the information required by the Company to effectuate the transfer. You are encouraged to discuss the proposed terms of any division of this Award with the Company&#8217;s General Counsel prior to finalizing the domestic relations order or marital settlement agreement to verify that you may make such transfer, and if so, to help ensure the required information is contained within the domestic relations order or marital settlement agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.</b></font><b style="font-weight:bold;">DATE OF ISSUANCE.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 4.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>The issuance of shares in respect of the Restricted Stock Units is intended to comply with Treasury Regulations Section 1.409A-1(b)(4) and will be construed and administered in such a manner. Subject to the satisfaction of the withholding obligations set forth in this Agreement, in the event one or more Restricted Stock Units vests, the Company shall issue to you one (1) share of Common Stock for each Restricted Stock Unit that vests on the applicable vesting date(s) (subject to any adjustment under Section 3 above). The issuance date determined by this paragraph is referred to as the &#8220;<font style="font-style:italic;font-weight:bold;">Original Issuance Date</font>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 4.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>If the Original Issuance Date falls on a date that is not a business day, delivery shall instead occur on the next following business day. In addition, if:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(i)</b><font style="display:inline-block;width:26.56pt;"></font>the Original Issuance Date does not occur (1) during an &#8220;open window period&#8221; applicable to you, as determined by the Company in accordance with the Company&#8217;s then-effective policy on trading in Company securities, or (2) on a date when you are otherwise permitted to sell shares of Common Stock on an established stock exchange or stock market, <i style="font-style:italic;">and</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(ii)</b><font style="display:inline-block;width:23.78pt;"></font>either (1) Withholding Taxes do not apply, or (2) the Company decides, prior to the Original Issuance Date, (A) not to satisfy the Withholding Taxes by withholding shares of Common Stock from the shares otherwise due, on the Original Issuance Date, to you under this Award, and (B) not to permit you to pay your Withholding Taxes in cash,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">then</u> the shares that would otherwise be issued to you on the Original Issuance Date will not be delivered on such Original Issuance Date and will instead be delivered on the first business day when you are not prohibited from selling shares of the Company&#8217;s Common Stock in the open public market, but in no event later than December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of your taxable year in which the Original Issuance Date occurs), or, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">if and only if</u> permitted in a manner that complies with Treasury Regulations Section 1.409A-1(b)(4), no later than the date that is the 15th day of the third calendar month of the applicable year following the year in which the shares of Common Stock under this Award are no longer subject to a &#8220;substantial risk of forfeiture&#8221; within the meaning of Treasury Regulations Section 1.409A-1(d).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 4.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>The form of delivery (<i style="font-style:italic;">e.g.</i>, a stock certificate or electronic entry evidencing such shares) shall be determined by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></font><b style="font-weight:bold;">DIVIDENDS. </b>You shall receive no benefit or adjustment to your Award with respect to any cash dividend, stock dividend or other distribution that does not result from a Capitalization Adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></font><b style="font-weight:bold;">RESTRICTIVE LEGENDS.</b> The shares of Common Stock issued under your Award shall be endorsed with appropriate legends as determined by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.</b></font><b style="font-weight:bold;">EXECUTION OF DOCUMENTS. </b>You hereby acknowledge and agree that the manner selected by the Company by which you indicate your consent to your Grant Notice is also deemed to be your execution of your Grant Notice and of this Agreement. You further agree that such manner of indicating consent may be relied upon as your signature for establishing your execution of any documents to be executed in the future in connection with your Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></font><b style="font-weight:bold;">AWARD NOT A SERVICE CONTRACT</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 4.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>Nothing in this Agreement (including, but not limited to, the vesting of your Award or the issuance of the shares subject to your Award), the Plan or any covenant of good faith and fair dealing that may be found implicit in this Agreement or the Plan shall: (i) confer upon you any right to continue in the employ of, or affiliation with, the Company or an Affiliate; (ii) constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or affiliation; (iii) confer any right or benefit under this Agreement or the Plan unless such right or benefit has specifically accrued under the terms of this Agreement or Plan; or (iv) deprive the Company of the right to terminate you at will and without regard to any future vesting opportunity that you may have.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 4.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>The Company has the right to reorganize, sell, spin-out or otherwise restructure one or more of its businesses or Affiliates at any time or from time to time, as it deems appropriate (a &#8220;<font style="font-style:italic;font-weight:bold;">reorganization</font>&#8221;). Such a reorganization could result in the termination of your Continuous Service, or the termination of Affiliate status of your employer and the loss of benefits available to you under this Agreement, including but not limited to, the termination of the right to continue vesting in the Award. This Agreement, the Plan, the transactions contemplated hereunder and the vesting schedule set forth herein or any covenant of good faith and fair dealing that may be found implicit in any of them do not constitute an express or implied promise of continued engagement as an employee or consultant for the term of this Agreement, for any period, or at all, and shall not interfere in any way with the Company&#8217;s right to conduct a reorganization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></font><b style="font-weight:bold;">WITHHOLDING OBLIGATIONS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 4.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>On each vesting date, and on or before the time you receive a distribution of the shares underlying your Restricted Stock Units, and at any other time as reasonably requested by the Company in accordance with applicable tax laws, you hereby authorize any required withholding from the Common Stock issuable to you and/or otherwise agree to make adequate provision in cash for any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or any Affiliate that arise in connection with your Award (the &#8220;<font style="font-style:italic;font-weight:bold;">Withholding Taxes</font>&#8221;). &#160;Additionally, the Company or any Affiliate may, in its sole discretion, satisfy all or any portion of the Withholding Taxes obligation relating to your Award by any of the following means or by a combination of such means: (i) withholding from any compensation otherwise payable to you by the Company; (ii) causing you to tender a cash payment; (iii) permitting or requiring you to enter into a &#8220;same day sale&#8221; commitment, if applicable, with a broker-dealer that is a member of the Financial Industry Regulatory Authority (a &#8220;<font style="font-style:italic;font-weight:bold;">FINRA Dealer</font>&#8221;) whereby you irrevocably elect to sell a portion of the shares to be delivered in connection with your Restricted Stock Units to satisfy the Withholding Taxes and whereby the FINRA Dealer irrevocably commits to forward the proceeds necessary to satisfy the Withholding Taxes directly to the Company and/or its Affiliates; or (iv) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to you in connection with the Award with a Fair Market Value (measured as of the date shares of Common Stock are issued to pursuant to Section 6) equal to the amount of such Withholding</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 4.5pt;">Taxes; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that the number of such shares of Common Stock so withheld will not exceed the amount necessary to satisfy the Company&#8217;s required tax withholding obligations using up to the maximum statutory withholding rates for federal, state, local and foreign tax purposes in the applicable jurisdiction, including payroll taxes, that are applicable to supplemental taxable income (or such lesser amounts as may be necessary to avoid classification of this Award as a liability for financial accounting purposes); and <i style="font-style:italic;">provided</i>, further, that to the extent necessary to qualify for an exemption from application of Section 16(b) of the Exchange Act, if applicable, such share withholding procedure will be subject to the express prior approval of the Company&#8217;s Compensation Committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 4.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>Unless the tax withholding obligations of the Company and/or any Affiliate are satisfied, the Company shall have no obligation to deliver to you any Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 4.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>In the event the Company&#8217;s obligation to withhold arises prior to the delivery to you of Common Stock or it is determined after the delivery of Common Stock to you that the amount of the Company&#8217;s withholding obligation was greater than the amount withheld by the Company, you agree to indemnify and hold the Company harmless from any failure by the Company to withhold the proper amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.</b></font><b style="font-weight:bold;">TAX CONSEQUENCES.</b> The Company has no duty or obligation to minimize the tax consequences to you of this Award and shall not be liable to you for any adverse tax consequences to you arising in connection with this Award. You are hereby advised to consult with your own personal tax, financial and/or legal advisors regarding the tax consequences of this Award and by signing the Grant Notice, you have agreed that you have done so or knowingly and voluntarily declined to do so. You understand that you (and not the Company) shall be responsible for your own tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">13.</b></font><b style="font-weight:bold;">UNSECURED OBLIGATION. </b>Your Award is unfunded, and as a holder of a vested Award, you shall be considered an unsecured creditor of the Company with respect to the Company&#8217;s obligation, if any, to issue shares or other property pursuant to this Agreement. You shall not have voting or any other rights as a stockholder of the Company with respect to the shares to be issued pursuant to this Agreement until such shares are issued to you pursuant to Section 6 of this Agreement. Upon such issuance, you will obtain full voting and other rights as a stockholder of the Company. Nothing contained in this Agreement, and no action taken pursuant to its provisions, shall create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">14.</b></font><b style="font-weight:bold;">NOTICES</b>. Any notice or request required or permitted hereunder shall be given in writing to each of the other parties hereto and shall be deemed effectively given on the earlier of (i) the date of personal delivery, including delivery by express courier, or delivery via electronic means, or (ii) the date that is five (5) days after deposit in the United States Post Office (whether or not actually received by the addressee), by registered or certified mail with postage and fees prepaid, addressed at the following addresses, or at such other address(es) as a party may designate by ten (10) days&#8217; advance written notice to each of the other parties hereto:</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:21.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:21.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">COMPANY:</b></p></td><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aclaris Therapeutics, Inc. </p></td></tr><tr><td style="vertical-align:bottom;width:21.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn: Stock Administrator</p></td></tr><tr><td style="vertical-align:bottom;width:21.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">701 Lee Road &#8211; Suite 103</p></td></tr><tr><td style="vertical-align:bottom;width:21.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Wayne, PA 19087</p></td></tr><tr><td style="vertical-align:bottom;width:21.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:21.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:21.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">PARTICIPANT:</b></p></td><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Your address as on file with the Company</p></td></tr><tr><td style="vertical-align:bottom;width:21.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">at the time notice is given</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">15.</b></font><b style="font-weight:bold;">HEADINGS</b>. The headings of the Sections in this Agreement are inserted for convenience only and shall not be deemed to constitute a part of this Agreement or to affect the meaning of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">16.</b></font><b style="font-weight:bold;">MISCELLANEOUS</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 4.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>The rights and obligations of the Company under your Award shall be transferable by the Company to any one or more persons or entities, and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by, the Company&#8217;s successors and assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 4.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 4.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>You agree that, in the event the Company proposes to offer for sale to the public any of its equity securities and you are so requested by the Company or any underwriter engaged by the Company in connection with such offering, you will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company held by you, for the period specified by the Company and the underwriters following the effective date of the registration statement of the Company filed under the Securities Act for such offering, such period not to exceed 180 days or such longer period as the underwriters or the Company will request to facilitate compliance with regulatory restrictions on (1) the publication or other distribution of research reports and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in applicable FINRA rules, or any successor or similar rule or regulation. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto.&#160;In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock until the end of such period.&#160;You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this Section 16(c). The underwriters of the Company&#8217;s stock are intended third party beneficiaries of this Section 16(c) and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 4.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font>You acknowledge and agree that you have reviewed your Award in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your Award and fully understand all provisions of your Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 4.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font>This Agreement shall be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 4.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(f)</b></font>All obligations of the Company under the Plan and this Agreement shall be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">17.</b></font><b style="font-weight:bold;">GOVERNING PLAN DOCUMENT</b>. Your Award is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your Award, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan. Your Award (and any compensation paid or shares issued under your Award) is subject to recoupment in accordance with The Dodd&#8211;Frank Wall Street Reform and Consumer Protection Act and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">any implementing regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable law. No recovery of compensation under such a clawback policy will be an event giving rise to a right to voluntarily terminate employment upon a resignation for &#8220;good reason,&#8221; or for a &#8220;constructive termination&#8221; or any similar term under any plan of or agreement with the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">18.</b></font><b style="font-weight:bold;">EFFECT ON OTHER EMPLOYEE BENEFIT PLANS.</b> The value of the Award subject to this Agreement shall not be included as compensation, earnings, salaries, or other similar terms used when calculating benefits under any employee benefit plan (other than the Plan) sponsored by the Company or any Affiliate except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any or all of the employee benefit plans of the Company or any Affiliate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">19.</b></font><b style="font-weight:bold;">CHOICE OF LAW.</b> The interpretation, performance and enforcement of this Agreement shall be governed by the law of the State of Delaware without regard to that state&#8217;s conflicts of laws rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">20.</b></font><b style="font-weight:bold;">SEVERABILITY</b>. If all or any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">21.</b></font><b style="font-weight:bold;">OTHER DOCUMENTS</b>. You acknowledge receipt of and the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus. &#160;In addition, you acknowledge receipt of the Company&#8217;s Insider Trading Policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">22.</b></font><b style="font-weight:bold;">AMENDMENT.</b> This Agreement may not be modified, amended or terminated except by an instrument in writing, signed by you and by a duly authorized representative of the Company. Notwithstanding the foregoing, this Agreement may be amended solely by the Board by a writing which specifically states that it is amending this Agreement, so long as a copy of such amendment is delivered to you, and provided that, except as otherwise expressly provided in the Plan, no such amendment materially adversely affecting your rights hereunder may be made without your written consent. Without limiting the foregoing, the Board reserves the right to change, by written notice to you, the provisions of this Agreement in any way it may deem necessary or advisable to carry out the purpose of the Award as a result of any change in applicable laws or regulations or any future law, regulation, ruling, or judicial decision, provided that any such change shall be applicable only to rights relating to that portion of the Award which is then subject to restrictions as provided herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">23.</b></font><b style="font-weight:bold;">COMPLIANCE WITH SECTION 409A OF THE CODE</b><i style="font-style:italic;">.</i> This Award is intended to comply with the &#8220;short-term deferral&#8221; rule set forth in Treasury Regulation Section 1.409A-1(b)(4). Notwithstanding the foregoing, if it is determined that the Award fails to satisfy the requirements of the short-term deferral rule and is otherwise deferred compensation subject to Section 409A, and if you are a &#8220;Specified Employee&#8221; (within the meaning set forth in Section 409A(a)(2)(B)(i) of the Code) as of the date of your &#8220;separation from service&#8221; (within the meaning of Treasury Regulation Section 1.409A-1(h) and without regard to any alternative definition thereunder), then the issuance of any shares that would otherwise be made upon the date of the separation from service or within the first six (6) months thereafter will not be made on the originally scheduled date(s) and will instead be issued in a lump sum on the date that is six (6) months and one day after the date of the separation from service, with the balance of the shares issued thereafter in accordance with the original vesting and issuance schedule set forth above, but if and only if such delay in the issuance of the shares is necessary to avoid the imposition of adverse taxation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">on you in respect of the shares under Section 409A of the Code. Each installment of shares that vests is intended to constitute a &#8220;separate payment&#8221; for purposes of Treasury Regulation Section 1.409A-2(b)(2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">* * * * *</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">This Restricted Stock Unit Award Agreement shall be deemed to be signed by the Company and the Participant upon the signing by the Participant of the Restricted Stock Unit Grant Notice to which it is attached.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ATTACHMENT II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;">2025 EQUITY INCENTIVE PLAN</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>acrs-20250605.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 6/5/2025 2:59:38 PM-->
<!--Modified on: 6/5/2025 2:59:38 PM-->
<xsd:schema targetNamespace="http://www.aclaristx.com/20250605" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:snj="http://xbrl.sec.gov/snj/2024" xmlns:acrs="http://www.aclaristx.com/20250605" xmlns:rxp="http://xbrl.sec.gov/rxp/2024q3" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:cyd-8k-sub="http://xbrl.sec.gov/cyd-8k-sub/2024" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="acrs-20250605_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="acrs-20250605_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>acrs-20250605_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 6/5/2025 2:59:38 PM-->
<!--Modified on: 6/5/2025 2:59:38 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>acrs-20250605_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 6/5/2025 2:59:38 PM-->
<!--Modified on: 6/5/2025 2:59:38 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="acrs-20250605.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638847323785986313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638847323785986313" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638847323785996662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638847323785996662" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638847323785996662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638847323785996662" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638847323785996662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638847323785996662" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638847323785996662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638847323785996662" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638847323785996662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638847323785996662" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638847323785996662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638847323785996662" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638847323785996662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638847323785996662" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638847323785996662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638847323785996662" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638847323785996662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638847323785996662" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638847323786006326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638847323786006326" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638847323786006326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638847323786006326" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638847323786006326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638847323786006326" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638847323786006326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications_638847323786006326" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638847323786006326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial_638847323786006326" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638847323786006326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638847323786006326" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638847323786006326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638847323786006326" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638847323786006326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638847323786006326" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638847323786016404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638847323786016404" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638847323786016404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638847323786016404" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638847323786016404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638847323786016404" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638847323786016404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638847323786016404" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638847323786016404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638847323786016404" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638847323786016404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638847323786016404" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 05, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  05,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Aclaris Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-0571712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">701 Lee Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wayne<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">324-7933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.00001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACRS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001557746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="acrs-20250605x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>acrs-20250605.xsd</File>
    <File>acrs-20250605_lab.xml</File>
    <File>acrs-20250605_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="acrs-20250605x8k.htm">acrs-20250605x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "acrs-20250605x8k.htm": {
   "nsprefix": "acrs",
   "nsuri": "http://www.aclaristx.com/20250605",
   "dts": {
    "schema": {
     "local": [
      "acrs-20250605.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "acrs-20250605_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "acrs-20250605_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "acrs-20250605x8k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acrs-20250605x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acrs-20250605x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Adress Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001558370-25-008430-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-25-008430-xbrl.zip
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M?A&5:@L;)?/XY>GQ3^>A)T/$MX14G4%.],;16\#Z]]:3M3+8'"NF+^D=%!B
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MVGC]4NA<MEM?7G!:MW*YLDR)328%$51MB-S3?ED @2?P$9UXYQ\IXF0]IO)
M/V((E*TQA:$ E(Q@AFM[QDGXF,KVIQ//K#<L0N7Y=*!.=NDY39==,9W*ACQB
MK5B(1U%%A$E<=&4:]+IB$A>Q1I"1^)2_OND7N,&7SZ-;_;4W@'V.$5V!ZKL^
M[8MS2F>23R5Y)7JO]ZQ+IC&F:/0DNHX^<MK'J(BK73:>QE1[" ;JN)ULF088
M<X'G_SIK8(,Z 4F+5'RXPXEJ[YYK5FN]FXYGTIZ #UG0)6\,0V+UZA9(8%9S
M_-I9B$:LRB1U"0"1PGM!E;V;_;0,?2)X".*MOZ<ET/\AD;WYX:P.E=5(0*#
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M/'0WT+_NMT)#,>5SH]K81T*+!DV8*1Z(7N#!9N<&>3<_KY;TL<?0,^C(#1M
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MV"8X[/9 0+X__HMC*Y'H4HN:2[.3G58L/#+FC_TQ@0)V"QEQVQ0+I::<I)[
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M:A+C0$\L][,("_+N4K\LQ -BDE.^>')V,ZIM_Z4%Q9Y,0;'/*BCVA:A6^>E
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M[Y1>PN?]&T+QIH(H7.[Y;,V_T@"8+F %38XH*3F;T!M.3\VJY.GC_S1/LI\
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MN+^\&O_N5"3Y 4&4[Z8@RF<51#D0'Z!RZ@-^0-\O%H PV]N)IH=),CWD-F0
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MG/JK>;W<PQ_K;E/^Y?\'4$L#!!0    ( #F Q5I!RSKL,"T  .A+ 0 8
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MGF#;*&/H+62!]-2TT.SEH7@CM0+]I@EHTZ"6I"J9P[\ZB\#6(VR%DI$6HKI
M32Q!ESZ,H33P6](V0<R0!DHJ^*\*E+DJ^ <!SXAWP#@UVS)%:.]GF:?13D0J
MX1&J0<TJ=6FO.RMS.(-  !'J- VHK%E#%X&//*P="F/(UJ61%&:1AS2' ;IF
M2&QX"HD-5\"<;R1+6P$5WZ7#;O$SY)]%.4L6Y $C<[*;XZ+VBOQKCL@V8.BN
M8YFTU.E>4W_2+RG6.IT&<8Z>6= 0&/WF(LE3Y+GK]C9Q?+5$-<DJ8RA>;.BD
M,+X; IM!/2A&%\<ZL[668HF#&'2%;>@*D:LK?/(1BBX#JFV!U!I0V@T2\J88
MM=ZEKFQ[N5V0> 6RJ:/^F*Q/OZ#+HY& P01[%OR ECE%*6P[QBR6,U0$UEHF
M)Y/J4$1(6XES;4*)J'1OU-O'748UHX0BL!&!BJK46" ;+0#L$=V5)4*MFHEL
M6&G'E&8KN#%_B;,T=H$9Y&GWNM)&9'F0YK!Q!?K37;Q"MLG:SGIYA^ *'2A"
M#@.31&34:@HG<K?H,$-%L"YU[)I$;9>_0S0]*Q!:_U0B;7K(IN0CQE/ )I[E
MQ0T16_PP>AFI8:93>I<W0+P'E?K*7\*QPZ7()\ ,&)1U<'1M@8\=W=K1]2>=
M;Z;K-1]7GR>8D+[1>&#NT,UMA@W>P@:_O/4&G[)9F<#8_J:6)#O2!-FI%Q?*
MD'UA,()AJ_M,.N!E*0*5.J[,+AE#C,R7,HHB%QH1D<_1@5)89Q6VY0R2(DE%
MB,P/N6/S>.C)OADYUME#K\5(]N.?)LO"=6 YXV;]C9DO1I:LOXA[+ Q^,T$H
M,JJ?-. /UDU ZI.IY%(BX4:!I)6(3[P:G&&\/7!&#A,W:F,9G*.OB$2A9UY+
MS'>S>IOX:HE=L]) 8CM\719%I!*(QSE(62"RE,=-9,-CI]<ZQSIB>Y]@($F*
MVP@EX7#;KBPX)?*1=O-G( ++,?HQQ\'^^,7>_NC+SN[^*-X9'>X0:30K-D1,
MML%GCF_-9Q#YOTN ]-M=>LKAS%90E*PDTG]8M[$7)<KQX]>M483D[)Y!_+U]
M_J@1=&Z5O3D\F*.A.;AX-)KMN$ES89-] T9VFJ!:/(0Z[CS4D<SG.DZ ,H!?
MV@U@!V?F&$,LM,Z3"^0X!1*9R8RY/'S+R2XU,NP(>'J)P0IB+RYR+AGQKG/U
M&NWNO!GH8MN>_6J&WG40!";UHF$65TN.H^UAV:1*?%)B5RKC39/TO9]M,@)R
M)"=18719GHEA),<@L(#- 8?8>7,)&+UY'9'HP\V/!K-\B:#,]"@+<?1+@4HB
M(A=!?JW)UEHM-'&3/.[*FW"-4/3^IYB$$O'IF!I/AR2ZKN6WEC)E-0%5)6!7
M(_JU<F-]]JJAUA1=RYF47&2^9 33<1H.7)@AM>[1Q9WB9Y.*5$1*HW%GQGOO
M^!!D0:B]6Q+653?97-\2XA9>?_-"&]8T?D9/ 1=(ZDO</.ONR[:W,<G*A/3S
M0I$VQS>8A*S%/_[-,HO>2!*SHK(8-UO11G?FM=W@SNU>8*/+_)97J I;+Q*K
M&[ .Z( F(27Y4YS-UY7Z)TE4?0M@UDG<>4D[J\Q9TE;66N/]L7EKDA)&;GF3
M%]:V@GR/Z-5D=$<N]66D-OJZ(R[,2CYXO],(<(.A7U+JW>CXBK/]T-'$K6E0
MVE[M=!V/;:H.W]L]'@/<Q1 ,_?;!T.]$._=B:=52IR .1OL'MY',C1'G:.'7
MTKM%\1[LKVWL<.SN,'V%FMIH_U5KCQTC27+:XT2;Y$#1M_HV':,)K(7TB-4K
MJ#&7&'8#,6R#&+3GI,F"2!=8_19$21'5<]17,:&M<9G9VEOC/^G*NU?ENDV)
MOK=AR[:Q95/??[)NB6VNL7X#AW/8ARWLPWE['S!/V/&#8_W.#/CJ7C7;\2IG
MNJYT?3AQCT_3MC]IP\6.8+V)!04B/I\0ZR#;5A+2DRS*P4#$S $57\ \%=W)
M6Y9YE!"%<NRLOP,VM6,;83(7XU84<*MH928:ID(!->%2?@2"BLG8[+9^Y]6Z
M7')VSO V9QVLG=]D3:Q,CLM$>[5=K=0A]GJ\GTY![X%V0U/8)BO%'F_3F2V>
M:C0E-QSBQDL;_Q/>*X8W=,=-(KOU=?J;R3':;AX_-7Y14\*$9?]R">=YK0B#
M03NA6<^(UWCCI2H2<C,&%8AL*J_;0#M&IS!U790"([?/E:P,E!UU+NY2<E8+
M%LO5:26QII^!1J+*!ITXB-S<@>>H%WEAAM#HGYVAK:9.;X.+@$BFW9LMWNN;
M0#.<AW/^'S%+?K6U6MP[1+SZSJ2D%P5<RT/"P]&J/VVQ+#$T$"*'@L&3%;E*
M)<.-'.T=T+F8N&!2BGLO2-P)3+*"IO@&>>G9S&@N?Y1+R*GB",:BR_[VA!,[
M&2ODL5VHE7'YMG+[Z&[ZS+O.T\VO ZFYQ@.M' +SN- 5J!,A9Q)3Q2D(6> G
MG/""P4\JE;63PGO8I?+7&33NAYT2"-S\7-/336:(043!VIIF7=9;D8P@DM-#
M8O-=%$$)_;1RASAN@*GH4O)'<K&)[TF==T^H(US;1]E":A9+6C-*7\VH&3^A
MF>0UCL94Q)K*.RXX[<C QW_Z\TC7TJX+GNRD\0)PI,0[3.WYT*GCF,&BM&$U
MJAD'"8 )4-#L%_P<ACW5"=ZVXN=D]V3#86S&))WT9H13T;D9 =*;>"DW9'*K
M2!(4R,[VDKB&<[1UIV;O.0K7#I*GH[N$"91/%79D]DRG<#[P!%#,T60CU4#5
M42!DC^)+,[A;V<3.3<H?T55.YXYE8=?-ORO6WO%B9^A.9^=@2JT]B5I]GF7B
M.FU8.(V10HU<K"Z!-RQ?#85(D8Q##%]F)3P; B?XHOG@S$ RFWAJ*!!K-*R%
MA2KA&0NB'#Z%DM#E&V"SZ/B<3CNL4P*;K0KN3#ECY< MG"AM0"W8X<0<C89
MS\$A6DCF%X^P\UC92@!GR5L,AO+<F5F%S40X+HU=)&[Q@>5*DHOJ[$?9)(_U
M^,G6DE&Q($5@U_PQ@7&P*9UV:H6ZW5/Z54:-VTHX!%2KL?]J#ZW=TFH"4M0@
M#XL0]R8BB] J2R'*Q(:G*D+3$F?5SO.4Q%&LL6DGBH[V=YQ38>NG1-G"14G
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M4@N?TD*B-T:?0H7QTJ374!(Q%JP2A<$#\-@TII.$_HE("J$X[UZOLL2%PQ%
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M0(TC78B!=\/$%E)X@WR5TFA<TGD-KNAX7Y/[FE8&+OM7'2>$Y0>*!DVO$]*
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ME!W@$'@>%O,=?5_F^U9.0T7Z-D9[-,KC!?PSK6;IJ_\/4$L#!!0    ( #F
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M9E9N&H\ZH$K;[RMNK5^OO *]I,'43/?1.60^(LWB3%=*C'"#-#_,IWRVYL7
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M9L>%8.%=O8YR^H.^LOT]X/]02P$"% ,4    "  Y@,5:-EG8!+(#  !R#0
M$0              @ $     86-R<RTR,#(U,#8P-2YX<V102P$"% ,4
M"  Y@,5:-]MQ8JP%   *00  %0              @ 'A P  86-R<RTR,#(U
M,#8P-5]L86(N>&UL4$L! A0#%     @ .8#%6M%>/-S-!   ^"D  !4
M         ( !P D  &%C<G,M,C R-3 V,#5?<')E+GAM;%!+ 0(4 Q0    (
M #F Q5JFA]GNVQ\  #8W 0 4              "  < .  !A8W)S+3(P,C4P
M-C U>#AK+FAT;5!+ 0(4 Q0    ( #F Q5K4$D(M,UX  '") @ 8
M      "  <TN  !A8W)S+3(P,C4P-C U>&5X,3!D,2YH=&U02P$"% ,4
M"  Y@,5:0<LZ[# M  #H2P$ &               @ $VC0  86-R<RTR,#(U
M,#8P-7AE>#$P9#(N:'1M4$L! A0#%     @ .8#%6AWU@LN5*P  +A(! !@
M             ( !G+H  &%C<G,M,C R-3 V,#5X97@Q,&0S+FAT;5!+ 0(4
M Q0    ( #F Q5KYUZN'\ 8  ) H   7              "  6?F  !A8W)S
I+3(P,C4P-C U>&5X,V0Q+FAT;5!+!08     "  ( !X"  ",[0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>acrs-20250605x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="acrs-20250605.xsd" xlink:type="simple"/>
    <context id="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001557746</identifier>
        </entity>
        <period>
            <startDate>2025-06-05</startDate>
            <endDate>2025-06-05</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Tc_5Hn0IablO0y-JcPun28d9A_2_1">0001557746</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Tc_2Hwg2sz7_kunFkyzC_husQ_3_1">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Tc_1L1NCkpkJEyDxwJWa7clAA_4_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Narr_iNOLyBiE-0K4DoSoHM4L2Q">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Narr_PTxkYtOmPESeXqdE8opc7A">2025-06-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Narr_rEAcB7O1iUOQ2shW0VUgUw">Aclaris Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Tc_coXjH-hIoU60DvoUajHCIA_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Tc_HZ2KKVnAHEyJeFoSpjvnJQ_1_2">001-37581</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Tc_ijhUFXKmKU65ScEj4jQzBg_1_4">46-0571712</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Narr_CTR6cdhffkiHzNW4gvV4UA">701 Lee Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Narr_q7hShblITUO_ge1pR2L3vA">Suite 103</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Narr__8S70FRukEKodoT2JV0EHQ">Wayne</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Narr_1cfKWHRhNUadxDFAsAwwHg">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Narr_jMEfqoTE4kqUCrYMn0yMEA">19087</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Narr_naR14vsZaU2CErYCvu_ROw">484</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Narr_7vkmsWXn60ikevZbs9bUKA">324-7933</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Narr_jBsHUK5W1kWxYFKn8ZKbOQ">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Narr_3NSSDBZddEOUGfVvXJeeIQ">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Narr_uk7Wf5eh9EOVA5TD-ftP1A">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Narr__X15Ps0Y7UeyorEsOfzVuQ">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Tc_aDZxAWwksk2e62KiuS6o1A_3_0">Common Stock, $0.00001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Tc_7EarXS1r9EWYw3TT94vKlg_3_2">ACRS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Tc_R2bXU6Os1kGbnsYv-LvP1A_3_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_6_5_2025_To_6_5_2025_R-UXdm9f6E2q-_x1i3S_nA"
      id="Narr_kLT3PU5s0ESJfgPFhWOtNw">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
